



APRIA HEALTHCARE®

26220 Enterprise Court, Lake Forest, California 92630-8405 (949) 639-2000 Visit us at: www.apria.com

LEADING CHANGE *in* HOMECARE.



APRIA HEALTHCARE®

2006 ANNUAL REPORT

IMPROVING QUALITY OF LIFE.



The MISSION STATEMENT

OUR MISSION is to be the first choice of patients and customers for their homecare needs.

WE WILL ACCOMPLISH THIS BY:

Exceeding our customers' expectations every day.

Demonstrating high clinical standards and compassion in patient care.

Being responsive and flexible.

WE WILL DELIVER ON OUR MISSION BY:

Demonstrating a customer-first approach in all that we do.

Leading changes in our industry.

Managing our business efficiently in order to deliver value and quality to our customers and shareholders.

Recognizing that every person in our company makes a difference.

Financial Summary

- ▶ Net revenues of \$1.52 billion represented a record for the Company and 2.9% growth over 2005. Excluding the effect of the 2006 Medicare reimbursement cuts (\$15.0 million), our growth was 4.0% for the year.
- ▶ Diluted earnings per share were \$1.75 versus 2005's \$1.37.
- ▶ The respiratory service line grew 2.3%, or 3.8% when adjusted for reimbursement reductions.
- ▶ Our infusion therapy service line grew 7.2% in 2006, reflecting our newly-segmented sales force and growth in almost every key therapy category.
- ▶ The Company reduced capital expenditures for patient service equipment from 7.1% of net revenues in 2005 to 6.6% in 2006, while days inventory on hand decreased from 77 in 2005 to 60 in 2006.
- ▶ Selling, Distribution & Administrative expenses, at 53% of net revenues, improved over 2005's expenses of 53.7%. At 2.6%, bad debt expense as a percentage of net revenues also improved over 2005's 3.2%.
- ▶ Operating cash flow was \$280.9 million compared to \$206.3 million in 2005, primarily driven by operational improvements in the billing and collection functions and a cash positive tax item of \$35.0 million primarily relating to the favorable IRS tax ruling regarding the deductibility of interest on the Company's convertible notes.
- ▶ Apria used these strong cash flows to retire debt obligations totaling \$155 million and to invest in core business initiatives and information systems upgrades.

The following table presents Apria's selected financial data for the five years ended December 31, 2006. The data set forth below have been derived from Apria's audited Consolidated Financial Statements and are qualified by reference to, and should be read in conjunction with, the Consolidated Financial Statements and related notes thereto and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in this report.

	For the Year Ending December 31,				
(in thousands, except per share data)	2006 ¹	2005 ²	2004 ³	2003 ⁴	2002 ⁵
STATEMENTS OF INCOME DATA:					
Net revenues.....	\$ 1,517,307	\$ 1,474,101	\$ 1,451,449	\$ 1,380,945	\$ 1,252,196
Net income.....	74,980	66,941	114,008	115,992	115,595
Basic net income per common share.....	\$ 1.77	\$ 1.39	\$ 2.31	\$ 2.17	\$ 2.12
Diluted net income per common share.....	\$ 1.75	\$ 1.37	\$ 2.27	\$ 2.15	\$ 2.08
BALANCE SHEET DATA:					
Total assets.....	\$1,168,496	\$1,185,898	\$1,107,664	\$1,043,435	\$ 795,656
Long-term obligations, including current maturities.....	487,145	645,320	480,858	500,763	269,368
Stockholders' equity.....	410,431	327,164	406,185	365,948	351,309

¹ Net revenue for 2006 reflects \$15.0 million in incremental Medicare reimbursement reductions for respiratory drugs, oxygen and oxygen equipment.


² Net income for 2005 reflects \$16.3 million in settlement costs and legal fees associated with the disposition of the previously reported federal investigation and qui tam lawsuits, net of taxes. Net revenues for 2005 were reduced by an incremental \$27.4 million in Medicare reimbursement reductions on respiratory medications, certain durable medical equipment items and oxygen-related equipment. The balance sheet data at December 31, 2005 reflects the repurchase of common stock with \$175.0 million in debt borrowed from Apria's revolving line of credit. Net income per share for 2005 reflects the effect of the share repurchase on weighted average shares.


³ Net income for 2004 reflects the write-off of deferred debt issuance costs of \$2.7 million associated with the November 2004 refinancing of the company's bank loans. Net revenues for 2004 were reduced by \$15.2 million in Medicare reimbursement reductions on respiratory medications.

⁴ The balance sheet data at December 31, 2003 reflects the issuance of convertible senior notes in the aggregate principal amount of \$250.0 million and the concurrent repurchase of common stock with \$100.0 million of the proceeds. Net income per share for 2003 reflects the effect of the share repurchase.

⁵ Net income for 2002 reflects the impact of the favorable outcome of an income tax dispute that was settled in the fourth quarter of 2002. The components of this impact include: income tax benefit of \$11.1 million, interest income of \$4.0 million and related professional fee expense of \$1.7 million. Effective January 1, 2002, Apria adopted Statement of Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets," and accordingly ceased amortizing goodwill.

Apria did not pay any cash dividends on its common stock during any of the periods set forth in the table above.





Lawrence M. Higby
Chief Executive Officer

“The objectives and strategies that we set forth at the beginning of 2006 have largely been achieved and in several areas were exceeded.”

DEAR SHAREHOLDERS,

In 2006, Apria Healthcare gained momentum. Our strategy for growing sales and leveraging our cost structure produced a solid year of performance with record revenues and many financial and strategic milestones. We successfully navigated through Medicare price reductions, restored sales growth in key product lines, increased market share and achieved significant cost reductions. We increased productivity in several areas and improved patient satisfaction scores. Additionally, we enhanced dialogue with the nation’s policymakers about the long-term importance and value of homecare. While these accomplishments are significant, there is still much work to be done.

GENERATING GROWTH

During 2006, growth was restored through a restructuring of our sales force and increased emphasis on our recruiting and training programs. Additionally, we implemented a Sales Management System for our respiratory/home medical equipment sellers which enables automated account management, revenue trending and increased key account targeting.

For the year, our respiratory therapy business grew 2.3% and infusion therapy gained 7.2%. Revenue growth was particularly strong in the second half of the year, with fourth quarter growth rates of 7.8% and 12.2% for respiratory therapy and home infusion therapy, respectively. During 2007, we expect to expand the Apria sales force by 25% as we increase the number of sales specialists for infusion therapy and penetrate key markets with strong respiratory potential. In 2006, our new agreement with CIGNA HealthCare was fully integrated within 90 days of launch. Kaiser Permanente’s agreement was extended through 2011. Aetna and

UnitedHealthcare expanded their contracts with Apria by narrowing their provider panels. With ongoing support from our clinical services, logistics and revenue management teams, we expect to see additional Medicare growth and managed care contract expansion in the months ahead.

GAINING PRODUCTIVITY

Technology investments such as our UPS routing and scheduling software and improved billing and collection system continued to drive operating efficiencies. These included a 5.4% increase in total stops for the year, performed with 7.6% fewer delivery professionals. Over 80% of all our claims are now filed electronically, and advanced telecommunication systems now track customer service levels. Steady productivity gains over the last four years include a 53% increase in transaction volume while labor and other operating expenses were leveraged, as evidenced by corresponding growth in the number of full-time employees of only 12%. To decrease capital expenditures we have markedly improved our inventory tracking and repair controls and patient care management processes. In clinical services, our respiratory therapists increased the average number of patients seen by 14% and performed almost 200,000 physician-prescribed home visits with our patients.

As a result of productivity initiatives in 2006, the Company once again saw steadily improving ratios in selling, distribution and administrative expenses. Additional investments in centralization and automation have reduced by 50 percent the number of billing centers since 2005, greatly improving Days Sales Outstanding and overall accounts receivable management. Cash posting improved by 3.9% and, as a result of a new initiative to streamline patient pay collections, credit card transactions for patients with co-payment balances rose 230% over the prior year.

“Our 2007 initiatives are all designed to further enhance the quality of the service experience for our patients and referral sources alike.”

IMPROVING PATIENT CARE

Apria’s scores for patient satisfaction also rose in 2006, demonstrating our strong belief that service quality is a key differentiator in our industry. Our 2007 initiatives are all designed to further enhance the quality of the service experience for our patients and referral sources alike. In the coming year, we will continue to invest in proven technologies that have the power to streamline our order intake process, customer communications and data management.

A major underpinning of all that we do is our commitment to independent accreditation and compliance. Almost 18 years ago, Apria was the first home respiratory/medical equipment provider to voluntarily seek and obtain accreditation from the Joint Commission on Accreditation of Healthcare Organizations (JCAHO). In 2006, Apria was presented with the “Ethics in America” award by an independent non-profit organization that recognized our system-wide commitment to compliance and ethical business practices.

INFLUENCING POLICIES


As a result of our recent efforts in Washington, D.C., policymakers have developed a deeper understanding of the homecare industry as a *service provider*, rather than just an *equipment supplier*. We now have a more open dialogue with the government—and legislators have a greater understanding of how Medicare policy changes can negatively impact beneficiaries and providers. Our exchanges with the Centers for Medicare and Medicaid Services (CMS) on competitive bidding, quality standards, industry accreditation and the implementation of the Deficit Reduction Act of 2005 resulted in the incorporation of much of our feedback into the final rules and plans. In 2007, we will continue to closely monitor Medicare program developments and engage in constructive dialogue with both CMS and other policymakers.

INCREASING OUR MOMENTUM


During 2006, awareness of the growing role of homecare also increased. Despite reimbursement pressures, the demand for lower-cost, higher quality-of-life alternatives to institutional care continues to increase. Technological advances – including ambulatory and portable oxygen systems, ambulatory infusion and enteral pumps and new biotech infusion therapies – are front-page news. Other key industry growth drivers include aging demographics, fewer hospital beds and longer life expectancies. By capitalizing on industry trends in 2007 and beyond, Apria is in an excellent position to realize additional acceleration and growth. To that end, we will continue to invest in programs and upgrades that increase efficiencies, leverage our broad product line and operating platform, grow revenues and, most importantly, enhance the quality of life for the 1.5 million patients we serve.

We hope you enjoy the following stories about how our patients have enriched the quality of their lives, partly due to our service and assistance. We look forward to another productive year together. We are deeply appreciative of our shareholders’ ongoing support.

Sincerely,



Lawrence M. Higby
Chief Executive Officer



David L. Goldsmith
Chairman of the Board



David L. Goldsmith
Chairman of the Board



“Staying independent is the most important thing in the world.”

Casey Adams,
Age 19

COLUMBIA, MISSOURI

After about 30 seconds watching the University of Missouri Tiger Wheelchair Basketball team play, you don't even notice the wheelchairs. With determination on his face Casey Adams, a guard for the team, works deftly to control the ball. Passing to other teammates. Shooting powerful shots. “We practice five days a week,” he says. “We're also in the weight room three days a week, we do cardio too – we're always busy.” With over 30 games a year and a team stacked with promising young freshmen, there's a lot of work to be done. But these athletes are experts at facing challenges head-on.

Born with Spina Bifida, Casey has been in a wheelchair since he was four years old. When it comes to mobility and the supplies he needs for daily life, Casey calls on Tami Morris, the local Apria Rehab Manager. “Casey is a sweetheart,” says Tami. “He tells you exactly what he needs. He's very self-sufficient.”

As a Broadcast Journalism student, Casey isn't at a loss for words either. “Apria is a great corporation,” he says enthusiastically. “If you have an emergency situation – a flat tire or something – they're more than willing to make sure you get what you need. Apria helps me stay mobile, active, assertive, confident ... to live a normal life.” Could the London 2012 Paralympics be in Casey's future? “I'd like to play at a higher level someday,” he says. “Playing for my country would be the ultimate goal.”



Apria's Rehabilitation Services Division provides state of the art power or manual wheelchair solutions for people of all ages with disabilities with the goal of improving safety, independence, and quality of life. Specially trained rehabilitation representatives provide individually fitted products to meet mobility, seating, and positioning needs.

◀ Casey Adams in action on the Missouri Tigers' home court.

“As a patient, you have to take charge of your disease. . . tell people what you need.”

Roxlyn (Lyn) Cole,
Age 68

LITTLETON, COLORADO

How do you deal with a diagnosis of emphysema?

Lyn Cole used hers as motivation. It was Valentine’s Day four years ago when Apria delivered Lyn’s first supplemental oxygen system. “I was so oxygen deprived,” she recalls, “I would eat breakfast then sleep for a couple of hours.” A former aquatics director who previously swam a mile a day, Lyn knew then that she had to take charge of managing her disease. “You have a choice – use it or lose it,” she says.

Last fall, after four years of training and building her strength, Lyn completed a half-marathon in 3 hours and 36 minutes, placing third in her age division. Just a few months ago, she climbed 1,014 steps to the top of a Denver skyscraper – with 15 pounds of oxygen in her backpack. “My starting point was a little more than 1.5 mph for 15 minutes,” Lyn recalls. “But you start where you are. If you can only go five steps, you aim for six steps. Just keep moving.”


Today, Lyn receives transtracheal oxygen therapy through a small tube in her windpipe. She gets oxygen delivered from her local Apria branch and uses Apria’s Great Escapes program during road trips to visit her mother in Florida. Her plans for the future? “I like to dream I’ll do a whole marathon someday,” she says with a smile.



Apria’s clinical respiratory therapists, who undergo extensive continuing education, performed almost 200,000 in-home patient visits in 2006. They helped patients like Lyn understand and better manage their conditions, reducing the need for hospital stays and emergency room visits.

Lyn Cole braves the weather with an ambulatory oxygen system secured in her jogging stroller. ►





“Every time
I have a
change of
medication,
Apria is
there right
away.”

Leonel Garcia,
Age 65

BAKERSFIELD, CALIFORNIA

In 1959 when computers filled entire rooms, Leonel Garcia came to the United States from Spain to work for IBM. In January 2006, when Leonel was diagnosed with Pulmonary Fibrosis, a computer that fits in your hand measured his blood oxygen level at just 67%. “All I know is, I was tired all the time,” Leonel says. “I had shortness of breath. I couldn’t do much exercise.” After five days in the hospital, Leonel went home with a prescription for supplemental oxygen from Apria.

Since then, Oved, an Apria Patient Service Technician has been stopping by to refill his tanks and check his equipment every week. “Apria has been terrific to me,” says Leonel. “Every time I have a change of medication Apria is there right away.” Today, Leonel is one of 12 in his region who are waiting for lung transplants. In the meantime he says, “I try to walk as much as possible.” He goes on shopping trips with his wife. And he exercises his mind reading books he buys online.

“I used to have 1,500 books,” he recalls fondly. “When I moved here, I donated them to the library. I put them in the slot on Saturdays and Sundays...50 to 75 books at a time.” As Leonel rebuilds his collection, he looks forward to a day when a strong new lung gives him the breath he needs to travel long distances – up north to see his grandchildren or perhaps back to Nicaragua someday. “I don’t know why,” says his wife Rina, “but I just believe he’s going to be all right.”



Customized UPS scheduling and routing software enables Apria to provide greater predictability and reliability for the 40,000 home deliveries we make to people like Leonel every day. Additional enhancements in 2007 will further increase the service quality for our patients.

◀ Leonel Garcia reads in his home in Bakersfield, California.

“Without
Apria,
I would
probably be
in a care
home right
now.”

Lana Russ,
Age 59

LACEY, WASHINGTON

Imagine having three children, a supportive husband, a successful career and an inability to absorb nutrients from your food. Imagine having several surgeries and dropping from 145 pounds to a low of 78. Sleeping for three-quarters of every hour. Unable to think straight or climb the stairs in your own home. Until your doctor prescribes a solution, literally.

In 1992, Lana Russ learned she had Familial Visceral Myopathy, an intestinal disorder about which very little is understood. She was in and out of surgery and emergency rooms until 2005 – when she learned to give herself Total Parenteral Nutrition (TPN) with the help of Apria Healthcare’s infusion nursing team. Now, almost two years later, an Apria pharmacist customizes a solution of vitamins, nutrients and medications for Lana every week and has them delivered overnight to her home. Each night, Lana plugs one into an intravenous port in her arm. “I start at six at night and finish at six in the morning,” she explains.

To keep her spirits up Lana learned to quilt. In the beginning she did appliqué work in a reclining position or cut fabric between naps. Now she has five projects going at once. But, she notes, what rebuilt her strength was Apria’s clinical support and regular Tai Chi classes. “I take my TPN with me...I set the backpack on the floor and move around it,” she says. Today, Lana weighs 110 pounds. She can climb the stairs and take day trips with her husband in the car. “My energy levels are so much higher,” she says, “it’s like we’re dating again.”



Each week, Lana Russ gets a call from Monica Olson, an Apria Pharmacy Technician in Redmond, Washington. “When I talk to patients, I have to make sure they’re not just telling me what I want to hear. So I pay attention to their voices. Their voices tell me what I need to know.”

Lana Russ practices Tai Chi near her home in Lacey, Washington. ▶



2006 Financial Report

Management's Discussion and Analysis of Financial Condition and Results of Operations

OVERVIEW

Apria operates in the home healthcare segment of the healthcare industry and provides services in the home respiratory therapy, home infusion therapy and home medical equipment areas. In all three lines, Apria provides patients with a variety of clinical and administrative support services and related products and supplies, most of which are prescribed by a physician as part of a care plan. Apria provides these services to patients in the home through approximately 475 branch locations throughout the United States.

Apria's branch locations are organized into three geographic divisions. Management evaluates operating results on a geographic basis and, therefore, views each division as an operating segment (previously 15 regions). All divisions provide the same products and services, including respiratory therapy, infusion therapy and home medical equipment and supplies. For financial reporting purposes, all the company's operating segments are aggregated into one reportable segment in accordance with the aggregation criteria of Statement of Financial Accounting Standards ("SFAS") No. 131, "Disclosures about Segments of an Enterprise and Related Information."

STRATEGY

Apria's strategy is to position itself in the marketplace as the low cost, quality provider of a broad range of home healthcare services to managed care and Medicare customers. The specific elements of its strategy are to:

- ▶ achieve strong organic sales growth and increase market share;
- ▶ leverage its nationwide infrastructure to reduce costs and expand profits;
- ▶ deliver superior customer service; and
- ▶ attract, develop and advance leaders within the company.

CRITICAL ACCOUNTING POLICIES

Apria's management considers the accounting policies that govern revenue recognition and the determination of the net realizable value of accounts receivable to be the most critical in relation to the company's consolidated financial statements. These policies require the most complex and subjective judgments of management. Additionally, the accounting policies related to goodwill, long-lived assets and income taxes require significant judgment.

Revenue and Accounts Receivable. Revenues are recognized on the date services and related products are provided to patients and are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including private insurers, prepaid health plans, Medicare and Medicaid. Due to the nature of the industry and the reimbursement environment in which Apria operates, certain estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim denial or account review. Accounts receivable are reduced by an allowance for doubtful accounts which provides for those accounts from which payment is not expected to be received, although services were provided and revenue was earned. Upon determination that an account is uncollectible, it is written-off and charged to the allowance.

Management performs various analyses to evaluate accounts receivable balances to ensure that recorded amounts reflect estimated net realizable value. Management applies specified percentages to the accounts receivable aging to estimate the amount that will ultimately be uncollectible and therefore should be reserved. The percentages are increased as the accounts age; accounts aged in excess of 360 days are reserved at 100%.

Management establishes and monitors these percentages through analyses of historical realization data, accounts receivable aging trends, other operating trends, the extent of contracted business and business combinations. Also considered are relevant business conditions such as governmental and managed care payor claims processing procedures and system changes. If indicated by such analyses, management may periodically adjust the uncollectible estimate and corresponding percentages. Further, focused reviews of certain large and/or problematic payors are performed to determine if overall reserve levels are sufficient.

Goodwill and Long-lived Assets. Goodwill arising from business combinations represents the excess of the purchase price over the estimated fair value of the net assets of the acquired business. Pursuant to SFAS No. 142, "Goodwill and Other Intangible Assets," goodwill is tested annually for impairment or more frequently if circumstances indicate the potential for impairment. Also, management tests for impairment of its intangible assets and long-lived assets on an ongoing basis and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Apria's goodwill impairment test is conducted at a "reporting unit" level and compares each reporting unit's fair value to its carrying value. The company has determined that its geographic divisions (previously its regions) are reporting units under SFAS No. 142. The measurement of fair value for each division is based on an evaluation of future discounted cash flows and is further tested using a multiple of earnings approach. In projecting its reporting units' cash flows, management considers industry growth rates and trends, known and potential reimbursement reductions, cost structure changes and local circumstances specific to a division. Based on its tests and reviews, no impairment of its goodwill, intangible assets or other long-lived assets existed at December 31, 2006. However, future events or changes in current circumstances could affect the recoverability of the carrying value of goodwill and long-lived assets. Should an asset be deemed impaired, an impairment loss would be recognized to the extent the carrying value of the asset exceeded its estimated fair market value.

Share-Based Compensation. Effective January 1, 2006, Apria adopted the provisions of SFAS No. 123R, "Share-Based Payment," which establishes accounting for equity instruments exchanged for employee services. Under the provisions of SFAS No. 123R, share-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employee's requisite service period (generally the vesting period of the equity grant). Prior to January 1, 2006, the company accounted for share-based compensation to employees in accordance with APB No. 25, "Accounting for Stock Issued to Employees," and related interpretations. The company also followed the disclosure requirements of SFAS No. 123, "Accounting for Stock-Based Compensation," as amended by SFAS No. 148, "Accounting for Stock-Based Compensation — Transition and Disclosure." The company elected to employ the modified prospective transition method as provided by SFAS No. 123R and, accordingly, financial statement amounts for the prior periods presented have not been restated to reflect the fair value method of expensing share-based compensation.

For the year ended December 31, 2006, the company recorded share-based compensation expense of \$5,762,000. All such compensation is reflected in the accompanying condensed consolidated income statement within the selling, distribution and administrative expense line item. Share-based compensation expense recognized in 2006 is based on awards ultimately expected to vest; therefore, it has been reduced for estimated forfeitures. SFAS No. 123R requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. In the pro forma information presented for periods prior to 2006, the company accounted for forfeitures as they occurred.

For the year ended December 31, 2006, Apria's adoption of SFAS No. 123R reduced the company's operating income and income before taxes by \$2,323,000 and net income was reduced by \$1,737,000. Basic and diluted earnings per share were each reduced by \$0.04 for the year ended December 31, 2006. The adoption of SFAS No. 123R did not affect cash flow.

The company estimates the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, the expected option term, the expected volatility of the company's stock over the option's expected term, the risk-free interest rate over the option's term, and the company's expected annual dividend yield. Apria's management believes

that the valuation technique and the approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of the company's stock options granted in 2006. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.

The key input assumptions that were utilized in the valuation of the stock options granted during the year ended December 31, 2006 are summarized in the table below.

Expected option term ¹	4.8 years
Expected volatility ²	27.3%
Risk-free interest rate ³	4.6%
Expected annual dividend yield.....	0%

¹ The expected option term is based on historical exercise and post-vesting termination patterns.

² Expected volatility represents a combination of historical stock price volatility and implied volatility from publicly-traded options on Apria's common stock.

³ The risk-free interest rate is based on the implied yield on a U.S. Treasury zero coupon issue with a remaining term equal to the expected term of the option.

As of December 31, 2006, total unrecognized stock-based compensation cost related to unvested stock options was \$4,739,000, which is expected to be expensed over a weighted-average period of 1.44 years; the total unrecognized stock-based compensation cost related to unvested restricted stock purchase rights was \$3,503,000, which is expected to be expensed over a weighted-average period of 3.10 years; and the total unrecognized stock-based compensation cost related to unvested restricted stock awards and units was \$9,388,000, which is expected to be expensed over a weighted-average period of 2.73 years.

Income Taxes. Apria provides for income taxes in accordance with provisions specified in SFAS No. 109, "Accounting for Income Taxes." Accordingly, deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities. These differences will result in taxable or deductible amounts in the future, based on tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences become deductible. In making an assessment regarding the probability of realizing a benefit from these deductible differences, management considers the company's current and past performance, the market environment in which the company operates, tax planning strategies and the length of carryforward periods. Valuation allowances are established when necessary to reduce deferred tax assets to amounts that are more likely than not to be realized. Further, the company provides for income tax issues not yet resolved with federal, state and local tax authorities.

CLINICAL EXPENSE RECLASSIFICATION

Respiratory therapy expenses presented within cost of net revenues are comprised primarily of employee salary and benefit costs or contract fees paid to respiratory therapists and other related professionals who are deployed to service a patient. Apria's respiratory therapy personnel are also engaged in a number of administrative and marketing tasks, and accordingly, these costs are classified within selling, distribution and administrative expenses and amounted to \$15.7 million in 2006 and \$18.8 million in 2005. This classification was adopted in 2005. During prior years, the data was not captured in the detail necessary to make a corresponding reclassification. Therefore, all respiratory therapy expenses for 2004 are classified within selling, distribution and administrative expenses and totaled \$50 million.

Nursing expenses presented within cost of net revenues are comprised primarily of employee salary and benefit costs and fees paid to contracted workers who are deployed to service a patient. The majority of these costs relate to the company's infusion therapy service line which were previously classified as selling, distribution and administrative expenses. Additional nursing costs that are currently, and were previously, presented within the cost of net revenues relate to a small ancillary nursing service business that generates approximately \$1.0 million in revenue annually. This classification was adopted in 2005. Certain nursing expenses incurred by the infusion therapy business, including administrative and marketing costs, remain within selling, distribution and administrative expenses and totaled \$4.0 million, \$3.9 million and \$4.2 million for 2006, 2005 and 2004, respectively.

MEDICARE REIMBURSEMENT

As more fully discussed under Item 1 — “Business — Government Regulation,” the following is a high-level summary of certain Medicare and governmental regulatory issues.

There are a number of legislative and regulatory activities by the Centers for Medicare and Medicaid Services, or CMS, that affect or may affect Medicare reimbursement policies for products and services provided by Apria. Certain material provisions are outlined below in chronological order.

In December 2003, the Medicare Prescription Drug, Improvement and Modernization Act of 2003, also referred to as the Medicare Modernization Act, or MMA, became law. The provisions contained therein that are significant to Apria are as follows:

- ▶ A freeze on annual payment increases for durable medical equipment. The freeze commenced in 2004 and will continue through 2008.
- ▶ Reimbursement reductions for five durable medical equipment categories — Under the MMA, reimbursement is based on the median price paid for such items on behalf of beneficiaries of federal employee health benefit plans. The new fee schedules for these products went into effect January 1, 2005, with the exception of oxygen and oxygen equipment which was implemented on April 8, 2005. Subsequent legislation has modified some of these reimbursement methodologies.
- ▶ Reimbursement reductions for inhalation drugs — The previous reimbursement rate of 95% of the average wholesale price was reduced to 80% of the average wholesale price, effective January 1, 2004. Beginning in January 2005, reimbursement for these drugs was further reduced to the quarterly manufacturer-reported average sales price, or ASP, plus 6%, plus a separate dispensing fee per patient episode. The company has no way of knowing if the quarterly ASPs for inhalation drugs will increase or decrease. Since 2006, dispensing fees have been \$57.00 for a 30-day supply for a new patient, \$33.00 for each 30-day supply thereafter, and \$66.00 for each 90-day supply. Additionally, in late December 2005, the 2006 fee schedule for Medicare Part B medications that took effect on January 1, 2006 included commercially manufactured budesonide (Pulmicort®)¹ and DuoNeb®².
- ▶ Establishment of a competitive bidding program for Medicare Part B — The program requires that suppliers wishing to provide certain durable medical equipment to beneficiaries submit bids to Medicare. Although the specific durable medical equipment items and services subject to this rule and the exact timeline for implementation remain unspecified, the MMA states that the program is to be phased in as follows: (i) 10 of the largest metropolitan statistical areas, or MSAs, in 2007; (ii) 80 of the largest MSAs in 2009; and (iii) additional urban areas after 2009.

On August 1, 2006, CMS issued a final rule limited to only selective operational aspects of the competitive bidding program. To date, a final rule for the remaining components of the competitive bidding program has not been published. Given the limited information available regarding CMS' final plan for the competitive bidding program, such as the list of products and services and the MSAs to be included, Apria cannot estimate at this time the impact of the competitive bidding program on the company's operations or financial condition.

- ▶ Reimbursement for home infusion therapy under Medicare Part D — Currently, a limited number of infusion therapies, supplies and equipment are covered by Medicare Part B. A bill was introduced in Congress in the summer of 2006 to consolidate home infusion therapy coverage under Part B and to provide for infusion benefit coverage in a comprehensive manner.

The Deficit Reduction Act of 2005, or DRA, was signed by the President in February 2006. The legislation contains the following provisions that will impact reimbursement to Apria:

- ▶ Effective on January 1, 2006, most items of durable medical equipment currently categorized in the capped rental category by CMS, will be considered purchased outright at the end of a 13 month

¹ Pulmicort® is a registered trademark of Astra Zeneca AB Corporation

² DuoNeb® is a registered trademark of Dey L.P.

maximum rental period (reduced from 15 months) and the ownership of such devices will transfer directly to the patients. The first month in which the new policy had an impact on the company's revenue was February 2007. In addition, the service and maintenance fee, which had been paid to suppliers twice yearly after the rental period ended in order to cover various non-equipment service costs, was eliminated for those patients who commenced service on or after January 1, 2006. Management estimates that the reduction in rental revenues for impacted DME products and the loss of the service and maintenance fees in 2007 will be approximately \$4.0 million and \$0.5 million, respectively. The 2007 estimate assumes the loss of service and maintenance fees for one quarter as the effect of the loss is expected to impact the latter part of the year only. However, this estimate is subject to assumptions and uncertainties and the actual negative impact on revenue and fees may be greater or less.

- ▶ Under the DRA, reimbursement for oxygen equipment will also convert from an ongoing rental method to a rent-to-purchase method. The law mandates that oxygen equipment reimbursement will be limited to 36 months, after which time the ownership of the equipment will transfer to the patient. The final rule that CMS issued in November 2006 regarding the implementation of the DRA establishes new payment classes with varying reimbursement amounts for oxygen equipment and contents. Beginning in 2008, Medicare will review the utilization patterns and make adjustments to the payment rates if needed in order to satisfy the statutory mandate of budget neutrality. The new DRA payment amounts went into effect January 1, 2007, but the 36-month rental period will be retroactively applied to January 1, 2006 for all beneficiaries requiring oxygen as of December 31, 2005. Accordingly, January 2009 is the first month in which the transfer of ownership for oxygen equipment and the new repair and maintenance policy will impact the company.

The final rule also limits supplier replacement of oxygen equipment during the rental period, and requires suppliers to replace beneficiary-owned equipment that does not last the useful lifetime of the equipment, which CMS has generally defined as being five years.

Regarding repair and maintenance, the final rule permits payment to suppliers for general maintenance and servicing of certain patient-owned oxygen equipment every six months, beginning after the first six months the patient owns the equipment. The final rule limits payment for general maintenance and servicing visits to 30 minutes of labor based on rates the Medicare contractors establish. CMS declined to offer general maintenance and servicing payments for beneficiary-owned liquid and gas equipment with the exception of a single payment for pick-up and storage or disposal of such equipment that a beneficiary no longer needs. Once title to the oxygen equipment transfers, CMS will also pay for certain other reasonable and necessary but non-routine repairs which remain as yet unspecified by the agency, but CMS will not make separate payment for certain patient support services, which are currently covered by and included in the monthly bundled payment rate for oxygen therapy. Apria may or may not continue to provide repair and maintenance service on patient-owned equipment and is in the process of evaluating the impact of these changes.

- ▶ The President's current healthcare proposals seek to further reduce the maximum rental period for oxygen equipment from the now-mandated 36 months to 13 months. There are other initiatives to reduce the rental period to 13 months, but it is uncertain whether any of these initiatives will ultimately be approved by Congress. There are also legislative provisions that have been introduced in Congress that would repeal the current oxygen reimbursement cap and equipment ownership mandate included in the DRA, but it is uncertain whether and when any of the OIG's recommendations or the repeal legislation ultimately would be adopted and passed by Congress.

Other outstanding issues that will or could have an impact on Medicare reimbursement levels to Apria are summarized as follows:

- ▶ In late December 2005, CMS issued the 2006 Health Care Procedure Coding System, or HCPCS, fee schedule for Medicare Part B medications and the new two-tiered dispensing fee for inhalation therapies. The fee schedule took effect on January 1, 2006, and included two HCPCS codes for

commercially manufactured budesonide (Pulmicort[®])³ and DuoNeb[®]⁴. The fee schedule also included a revised definition for the HCPCS codes for commercially manufactured budesonide and budesonide compounded from a powder, and separated these products into two unique codes.

- ▶ In January 2006, CMS published a final regulation that would shift payment for certain respiratory assist devices from ongoing rental method to a rent-to-purchase method. The change in the payment method became effective April 1, 2006. The policy applies to those respiratory assist devices (known as BiPAP STs) that have a backup rate feature that delivers pressure whenever the user's spontaneous breathing efforts are insufficient. The first month in which the new categorization will impact the company's revenue will be May 2007. The company's estimate for this change in payment categories is a reduction in 2007 revenues of \$3 million.
- ▶ In January 2006, CMS announced and later modified the designation of four specialty contractors, DME MACs, which will be responsible for handling the administration of all Medicare claims from suppliers of durable medical equipment. It is difficult at this time to predict precisely how this change in claims administration will affect DME suppliers, nor can the company predict or estimate the potential impact of this change on collections of its accounts receivable.
- ▶ On March 24, 2006, the three Program Safeguard Contractors, or PSCs, overseeing durable medical equipment issued a proposed Local Coverage Determination, or LCD, for nebulizer medications covered by Medicare Part B. Specifically, four provisions were proposed: (i) payment for levalbuterol (commercially manufactured as brand-name Xopenex[®])⁵ would be based on the allowable for generic albuterol sulfate; (ii) payment for commercially-manufactured, brand-name DuoNeb[®] would be based on the allowance for separate unit dose vials of albuterol sulfate and ipratropium bromide; (iii) coverage for a variety of other nebulizer drugs would be eliminated because the PSCs assert that there is inadequate support in the medical literature for administration using a DME nebulizer; and (iv) maximum monthly utilization limits for budesonide would be defined.

The company believes that the MMA is clear in its intent to prescribe the Part B average sales price reimbursement formula for single-source drugs which applies to both DuoNeb[®] and Xopenex[®]. The company further believes that the PSCs do not have the legal authority to circumvent the average sales price methodology through the issuance of an LCD that invokes their authority to use the "Least Costly Alternative" as the basis for reducing the reimbursement for these drugs. The company has determined that if the four provisions of the LCD are implemented as proposed in the March 24, 2006 document, it will generally not provide DuoNeb[®] and Xopenex[®] to existing or future patients covered by Medicare. Management's current estimate of providing the replacement medications in lieu of the brand name drugs is a quarterly gross profit reduction of approximately \$3 million. (Given that the impact for 2007 will only be for a partial year, a quarterly estimate is provided.) However, this estimate is subject to assumptions and uncertainties and the actual negative impact on gross profit may be greater or less.

Subsequent to the actions taken by the PSCs in the spring of 2006, CMS initiated a National Coverage Analysis on December 20, 2006 regarding the same issues of coverage and payment for certain inhalation drugs. CMS has indicated that it will issue a final decision in the third quarter of 2007, for implementation in the fourth quarter of 2007 at the earliest. Depending on the final outcome of such a decision by CMS, the company may or may not continue to provide DuoNeb[®] and Xopenex[®] to Medicare beneficiaries after a revised policy is implemented by CMS.

- ▶ In late 2006, CMS announced that it has revised the LCD for power mobility devices resulting in reductions to the power mobility devices fee schedule. The revised fee schedule imposes reductions for certain power mobility devices of about 15%. The changes took effect on November 15, 2006. Management's estimate of the annualized reduction in Apria's revenues resulting from these fee schedule changes is approximately \$1 million. However, this estimate is subject to assumptions and uncertainties and the actual negative impact on revenue may be greater or less.

³ Pulmicort[®] is a registered trademark of Astra Zeneca AB Corporation

⁴ DuoNeb[®] is a registered trademark of Dey L.P.

⁵ Xopenex[®] is a registered trademark of Sepracor, Inc.

Apria cannot estimate the combined possible impact of all legislative, regulatory and contemplated reimbursement changes that could have a material adverse effect on Apria's results of operations, cash flow and capital resources.

Results of Operations

NET REVENUES

Net revenues were \$1,517 million in 2006, \$1,474 million in 2005 and \$1,451 million in 2004. Growth rates were 2.9% and 1.6% in 2006 and 2005, respectively. The growth for both years was volume-based. The growth rates for 2006 and 2005 were impacted by Medicare reimbursement reductions newly imposed on each year. In 2005, Medicare reimbursement reductions include those that went into effect January 1, 2005 for respiratory drugs and certain durable medical equipment items. An additional reduction on oxygen and oxygen equipment went into effect April 8, 2005. The combined reduction totaled \$27.4 million in 2005. Growth for 2006 was impacted by the oxygen reduction for the period in early 2006 prior to the April 8 anniversary date. Further, a pricing reduction for dispensing fees for respiratory drugs went into effect January 1, 2006 and the average sales prices, which are used as the basis for Medicare reimbursement of respiratory drugs and are updated each quarter, were generally lower in 2006 than in 2005. The combined incremental effect on 2006 caused by these Medicare reductions was \$15.0 million. Adjusted for the Medicare pricing reductions, growth rates for 2006 and 2005 were 4.0% and 3.5%, respectively. Incremental revenues from acquisitions during each year were estimated at \$68.0 million for 2005 and \$21.3 million for 2006.

Apria expects to continue to face pricing pressures from Medicare as well as from its managed care customers as these payors seek to lower costs by obtaining more favorable pricing from providers such as Apria. In addition to the pricing reductions, such changes could cause Apria to provide reduced levels of certain products and services in the future, resulting in a corresponding reduction in revenue. However, given Apria's high volume of managed care business, it is well-positioned among its competitors with respect to the Medicare Advantage plan expansion. See "Medicare Reimbursement."

The following table sets forth a summary of net revenues by service line:

	Year Ended December 31,		
(in thousands)	2006	2005	2004
Home respiratory therapy	\$1,033,267	\$1,009,752	\$ 990,857
Home infusion therapy	274,723	256,225	246,662
Home medical equipment/other	209,317	208,124	213,930
Total net revenues	\$1,517,307	\$1,474,101	\$1,451,449

Respiratory Therapy. Respiratory therapy revenues are derived primarily from the provision of oxygen systems, home ventilators, sleep apnea equipment, nebulizers, respiratory medications and related services. Revenues from the respiratory therapy service line increased by 2.3% in 2006 and by 1.9% in 2005. The majority of the Medicare pricing reductions discussed above impacted the respiratory therapy line. Such reductions were \$15.0 million in 2006 and \$24.3 million in 2005. Adjusted for the Medicare reductions, respiratory revenues increased by 3.8% and 4.4% in 2006 and 2005, respectively. The growth was largely related to revenues from the continuous positive and bi-level airway pressure devices and related supplies. These revenues currently comprise approximately 28% of total respiratory revenues, and grew by 15.3% in 2006. Much of this growth was derived through a program the company has instituted to provide via mail the necessary supplies to patients already utilizing the airway pressure devices. Oxygen revenues, as adjusted for Medicare pricing reductions, increased by 1.2% in 2006 and respiratory medication revenues increased by 5.0%, also on an adjusted basis. Acquisitions of respiratory businesses were the primary driver of respiratory therapy revenue growth in 2005.

Infusion Therapy. The infusion therapy service line involves the administration of drugs or nutrients directly into the body intravenously through a needle or catheter. Infusion therapy services also include administering enteral nutrients directly into the gastrointestinal tract through a feeding tube. Infusion therapy revenues increased by 7.2% in 2006 and 3.9% in 2005. This growth was primarily related to revenues from enteral nutrition, which comprise just under half of the infusion therapy line, and which grew by 12.7% in 2006 and by 9.0% in 2005. This growth is due mainly to internal organizational changes and the management focus that has been placed on this sub-category.

Home Medical Equipment/Other. Home medical equipment/other revenues are derived from the provision of equipment to assist patients with ambulation, safety and general care in and around the home. Home medical equipment/other revenues increased by 0.6% in 2006 and decreased by 2.7% in 2005. In 2005, \$3.1 million of the Medicare reimbursement reductions impacted this line of business. Additionally, hospital utilization rates for many of the company's managed care contractors were down in the last half of 2005, which served to further depress growth in home medical equipment/other revenues.

GROSS PROFIT

Gross margins were 65.6% in 2006, 67.5% in 2005, and 71.2% in 2004. The decline in 2006 from 2005 was primarily caused by the Medicare reimbursement reductions, managed cared pricing reductions, as well as shifts in product mix to lower margin items. Further, certain of the Medicare reimbursement changes forced the company to provide higher cost items without corresponding revenue increases. The comparison between 2005 and 2004 was impacted by many of the same issues, but also reflects the change in classification of the clinical costs. The respiratory therapy expenses that were reclassified in 2005 (detailed data was not available for 2004) accounts for 2.2% of the variance between the two years. See "Clinical Expense Reclassification" above.

PROVISION FOR DOUBTFUL ACCOUNTS

The provision for doubtful accounts is based on management's estimate of the net realizable value of accounts receivable after considering actual write-offs of specific receivables. Accounts receivable estimated to be uncollectible are provided for by applying specific percentages to each receivables aging category, which is determined by the number of days the receivable is outstanding. For 2006, 2005 and 2004, the provision for doubtful accounts, expressed as percentages of net revenues, was 2.6%, 3.2% and 3.3%, respectively. The improvement in 2006 from the 2005 and 2004 levels is due to increased cash collections and the success of a credit card program designed to collect patient receivables upon delivery and automatically on the rental due date thereafter.

SELLING, DISTRIBUTION AND ADMINISTRATIVE

Selling, distribution and administrative expenses are comprised of expenses incurred in direct support of operations and those associated with administrative functions. Expenses incurred by the operating locations include salaries and other expenses in the following functional areas: selling, distribution, intake, reimbursement, warehousing and repair. Many of these operating costs are directly variable with revenue growth patterns. Some are also very sensitive to market-driven price fluctuations such as facility lease and fuel costs. The administrative expenses include overhead costs incurred by the operating locations and corporate support functions. These expenses do not fluctuate with revenue growth as closely as do operating costs. Certain clinical expenses previously classified in this line have been reclassified to cost of net revenues. See "Clinical Expense Reclassification" above.

The selling distribution and administrative percentages for 2005 are not comparable to 2004 due to the respiratory therapy costs that were not reclassified in 2004 to conform to the 2005 presentation. Adjusted for this impact, selling, distribution and administrative expense expressed as a percentage of net revenues increased 2.4% in 2005 versus 2004. Approximately half of this increase is attributable to the lower revenues resulting from the Medicare and managed care pricing changes without a corresponding reduction in the company's

actual cost of providing those products and services. Higher fuel prices and vehicle maintenance expenditures, rising medical benefit costs, outsourced collection fees and severance charges also factored into the increase. Further, advertising costs related to the company's diabetic supply business increased year to year as a result of the company's entry into this market late in the first quarter of 2004.

QUI TAM SETTLEMENT AND RELATED COSTS

As previously reported, Apria was the subject of an investigation launched in mid-1998 by the U.S. Attorney's office in Los Angeles and the U.S. Department of Health and Human Services. The investigation concerned the documentation supporting Apria's billing for services provided to patients whose healthcare costs were paid by Medicare and other federal programs. The investigation related to two civil *qui tam* lawsuits against Apria filed by individuals suing on behalf of the government. Apria and representatives of the government and the individual plaintiffs reached a preliminary agreement in early August 2005 to settle these lawsuits for the aggregate sum of \$17.6 million, without any admission of wrongdoing by Apria. The settlement was finalized in a definitive agreement that was fully executed and became effective on September 30, 2005, and Apria paid the settlement amount on that date. Apria also incurred \$1.7 million in legal fees and other related costs during 2005.

AMORTIZATION OF INTANGIBLE ASSETS

Amortization of intangible assets was \$5.1 million in 2006, \$6.9 million in 2005 and \$6.7 million in 2004. The decrease in amortization expense in 2006, when compared to 2005 and 2004, is due to the slowdown in the company's acquisition activity. See "Liquidity and Capital Resources — Business Combinations."

INTEREST EXPENSE, INTEREST INCOME AND WRITE-OFF OF DEFERRED DEBT ISSUANCE COSTS

Interest expense was \$31.2 million in 2006, \$23.0 million in 2005 and \$20.8 million in 2004. The increase in interest expense in 2006 is primarily attributable to the increase in long-term debt incurred near the end of 2005 to repurchase \$175 million of Apria's common stock. Higher interest rates in 2006 also contributed to the increase, which was mitigated by the debt repayments made over the course of 2006. The increase in interest expense in 2005, when compared to 2004 was due to the addition of the \$175 million in debt noted above and higher base interest rates. Interest income was \$1.7 million, \$853,000 and \$779,000 in 2006, 2005 and 2004, respectively.

In 2004, the company wrote off \$2.7 million in unamortized debt issuance costs in conjunction with the November 2004 refinancing of the company's bank loans.

INCOME TAX EXPENSE

Income taxes were \$43.3 million in 2006. The increase was mitigated by the release of \$4.0 million of federal and state tax contingencies due to the completion of a federal income tax audit during 2006. Income taxes were \$40.4 million and \$64.3 million for 2005 and 2004, respectively, and were provided at the effective tax rates expected to be applicable for each year.

The company has various apportioned state net operating loss carryforwards of \$8.4 million, net of federal tax benefit, as of December 31, 2006.

The company believes it has adequately provided for income tax issues not yet resolved with federal, state and local tax authorities. At December 31, 2006, \$12.2 million, net of tax benefit, was accrued for federal, state and local tax matters and is included in income tax payable. Although not probable, the most adverse resolution of these federal, state and local issues could result in additional charges to earnings in future periods in addition to the \$12.2 million currently provided. Based upon a consideration of all relevant facts and circumstances,

the company does not believe the ultimate resolution of tax issues for all open tax periods will have a materially adverse effect upon its results of operations or financial condition.

INFLATION

Apria experiences pricing pressures in the form of continued reductions in reimbursement rates, particularly from managed care organizations and from governmental payors such as Medicare and Medicaid. The company is also impacted by rising costs for certain inflation-sensitive operating expenses such as labor and employee benefits, facility and equipment leases, and vehicle fuel. However, Apria generally does not believe these impacts are material to its revenues or net income.

Liquidity and Capital Resources

Apria's principal source of liquidity is its operating cash flow, which is supplemented by a \$500 million revolving credit facility. In recent years, Apria has generated operating cash flows in excess of its operating needs, which has afforded it the ability to pursue acquisitions and fund patient service equipment purchases to support revenue growth. Apria's management believes that its operating cash flow will continue to be sufficient to fund its operations and growth strategies. In September 2008, the holders of the \$250.0 million convertible senior notes will have an opportunity to require Apria to repurchase some or all of the notes. Accordingly, Apria management continues to evaluate its financing alternatives regarding its ability to repurchase these notes to the extent required by the holders.

Further, Apria has initiated a project to implement a new enterprise-wide information system. The overall objective of the project is to deliver the necessary technology and automation across the organization to enable improvements in service, productivity and access to information. Development on certain modules commenced in 2006. The overall project plan is being designed and developed and is expected to be implemented over several years.

CASH FLOW

Cash provided by operating activities in 2006 was \$280.9 million compared to \$206.3 million in 2005 and \$271.6 million in 2004. The increase in 2006 is due primarily to a favorable IRS ruling on the deductibility of interest on the company's convertible notes, increased cash collections resulting from initiatives to optimize billing processes and to increase collections of patient copayments, and timing-related decreases in working capital requirements. The improvement was achieved despite the Medicare and managed care pricing decreases and related product cost increases noted above. The decrease in operating cash flow in 2005, when compared to 2004 levels, was primarily due to the Medicare reimbursement reductions and related product cost increases; the *qui tam* lawsuit settlement and related fees and an increase in tax payments between the periods, each as noted above.

Cash used in investing activities was \$132.9 million, \$223.6 million and \$281.4 million in 2006, 2005 and 2004, respectively. The sharp drop in 2006 is due to the reduced level of business combinations compared to the previous years. The reduction in purchases of patient service and other equipment in 2006 and 2005, when compared to 2004, is directly attributable to controls placed on inventory and purchasing.

Cash used in financing activities was \$156.6 million in 2006 versus \$1.2 million provided in 2005 and \$111.4 million used in 2004. The 2006 figure reflects the \$155.0 million net reduction of the company's revolving line of credit. In 2005, the company borrowed from its revolving credit facility to repurchase \$175.0 million worth of its common stock. Cash used in 2004 primarily relates to a \$100.0 million stock repurchase and scheduled principal payments made against term loans in place at the time.

CONTRACTUAL CASH OBLIGATIONS

The following table summarizes Apria's long-term cash payment obligations to which the company is contractually bound:

(in millions)	For the Year Ending December 31,						Total
	2007	2008	2009	2010	2011	2012+	
Revolving loan ¹	\$ —	\$ —	\$ —	\$ —	\$235	\$ —	\$235
Convertible senior notes ²	—	—	—	—	—	250	250
Other debt	2	—	—	—	—	—	2
Operating leases	56	47	36	26	18	22	205
Software licenses and related maintenance	1	1	—	—	—	—	2
Total contractual cash obligations	\$ 59	\$ 48	\$ 36	\$ 26	\$253	\$272	\$694

¹ Interest on the outstanding borrowings is payable quarterly.

² The holders of the convertible senior notes will first have the option to require Apria to repurchase all or a portion of their notes in September 2008. Interest on these notes is paid bi-annually in March and September.

ACCOUNTS RECEIVABLE

Accounts receivable before allowance for doubtful accounts decreased to \$238.4 million as of December 31, 2006 from \$268.0 million at December 31, 2005. Days sales outstanding (calculated as of each period-end by dividing accounts receivable, less allowance for doubtful accounts, by the 90-day rolling average of net revenues) were 49 days at December 31, 2006, compared to 57 days at December 31, 2005. The decrease in accounts receivable and days sales outstanding is a direct result of the aforementioned improvement in cash collections.

Accounts aged in excess of 180 days of total receivables for certain major payor categories, and in total, are as follows:

	December 31,	
	2006	2005
Total	19.8%	21.1%
Medicare	19.2%	22.8%
Medicaid	28.6%	28.7%
Self pay	36.5%	35.9%
Managed care/other	19.1%	19.4%

Unbilled Receivables. Included in accounts receivable are earned but unbilled receivables of \$30.0 million and \$39.0 million at December 31, 2006 and 2005, respectively. Delays, ranging from a day up to several weeks, between the date of service and billing can occur due to delays in obtaining certain required payor-specific documentation from internal and external sources. Earned but unbilled receivables are aged from date of service and are considered in Apria's analysis of historical performance and collectibility. The lower unbilled amount at the end of 2006 is largely due to the significant decrease in acquisition activity in 2006. The acquisitions executed in 2005 were the primary cause of the higher unbilled receivable balance at the end of that year. The time-consuming processes of converting patient files onto Apria's systems and obtaining provider numbers from governmental payors routinely delay billing of newly acquired business.

INVENTORIES AND PATIENT SERVICE EQUIPMENT

Inventories consist primarily of pharmaceuticals and disposable products used in conjunction with patient service equipment. Patient service equipment consists of respiratory and home medical equipment that is provided to in-home patients for the course of their care plan, normally on a rental basis, and subsequently returned to Apria for redistribution after cleaning and maintenance is performed.

The branch locations serve as the primary point from which inventories and patient service equipment are delivered to patients. Certain products and services, such as infusion therapy and respiratory medications, bypass the branches and are provided directly to patients from pharmacies or other central locations. The branches are supplied with inventory and equipment from central warehouses that service specific areas of the country. Such warehouses are also responsible for repairs and scheduled maintenance of patient service equipment, which adds to the frequent movement of equipment between locations. Further, the majority of Apria's patient service equipment is located in patients' homes. While utilization varies widely between equipment types, on the average, approximately 82% of equipment is on rent at any given time. Inherent in this asset flow is the fact that losses will occur. Management has successfully instituted a number of controls over the company's inventories and patient service equipment to minimize such losses. Depending on the product type, the company performs physical inventories on an annual or quarterly basis. Inventory and patient service equipment balances in the financial records are adjusted to reflect the results of these physical inventories. Inventory and patient service equipment losses for 2006, 2005 and 2004, were \$3.1 million, \$868,000 and \$2.0 million, respectively.

LONG-TERM DEBT

Apria's senior secured credit agreement with Bank of America and a syndicate of lenders was amended effective June 23, 2006. The amendment extended the maturity date from November 23, 2009 to June 23, 2011 and lowered the applicable interest rate margins and commitment fees. The credit agreement is structured as a \$500.0 million revolving credit facility. The credit agreement permits Apria to select one of two variable interest rates. One option is the base rate, which is expressed as the higher of (a) the Federal Funds rate plus 0.50% or (b) the Bank of America prime rate. The other option is the Eurodollar rate, which is based on the London Interbank Offered Rate. Interest on outstanding balances under the credit agreement is determined by adding a margin to the Eurodollar rate or base rate in effect at each interest calculation date. The applicable margin for the revolving credit facility is based on Apria's debt rating as determined by Standard and Poor's Ratings Services or Moody's Investor Services with respect to the credit facility. The applicable margins, as amended, range from 0.625% to 1.25% for Eurodollar loans and from zero to 0.25% for base rate loans. The credit agreement also requires payment of commitment fees ranging from 0.10% to 0.20% (also based on Apria's debt rating) on the unused portion of the revolving credit facility. The effective interest rate at December 31, 2006, after consideration of the effect of the swap agreements described below, was 6.25%. See "Hedging Activities."

On December 31, 2006 outstanding borrowings on the revolving credit facility were \$235.0 million, outstanding letters of credit totaled \$3.9 million and credit available under the revolving facility was \$261.1 million. At December 31, 2006, the company was in compliance with all of the financial covenants required by the credit agreement. Borrowings under the credit facility are secured by a pledge of the common stock of all of the company's subsidiaries.

Convertible Senior Notes. In August 2003, Apria issued convertible senior notes in the aggregate principal amount of \$250.0 million under an indenture between Apria and U.S. Bank National Association. The notes were issued in a private placement at an issue price of \$1,000 per note (100% of the principal amount at maturity) and were subsequently registered with the Securities and Exchange Commission. The notes will mature on September 1, 2033, unless earlier converted, redeemed or repurchased by Apria. Apria may redeem some or all of the notes at any time after September 8, 2010 at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest and contingent interest, if any, to the redemption date. The holders of the notes may require Apria to repurchase some or all of the notes at a repurchase price equal to 100% of the principal amount of the notes plus accrued and unpaid interest, including contingent interest, up to but excluding the applicable repurchase date, initially on September 1, 2008, and subsequently on September 1 of 2010, 2013, 2018, 2023 and 2028, or at any time prior to their maturity following a fundamental change, as defined in the indenture. Any notes that Apria is required to repurchase will be paid for in cash, pursuant to the terms of a December 2004 amendment to the indenture which eliminated the company's option to pay part of the repurchase price in shares of common stock.

The notes bear interest at the rate of 3¾% per year. Interest on the notes is payable on September 1 and March 1 of each year, beginning on March 1, 2004. Also, during certain periods commencing on September 8, 2010, Apria will pay contingent interest on the interest payment date for the applicable interest period if the average trading price of the notes during the five trading days ending on the third day immediately preceding the first day of the applicable interest period equals or exceeds 120% of the principal amount of the notes. The contingent interest payable per note will equal 0.25% per year of the average trading price of such note during the applicable five trading-day reference period. Further, the notes are convertible, at the holders' option, during certain periods into shares of Apria common stock, initially at a conversion rate of 28.6852 shares of common stock per \$1,000 principal amount of notes, subject to adjustment in certain events, under certain circumstances as outlined in the indenture.

Hedging Activities. Apria is exposed to interest rate fluctuations on its underlying variable rate long-term debt. Apria's policy for managing interest rate risk is to evaluate and monitor all available relevant information, including but not limited to, the structure of its interest-bearing assets and liabilities, historical interest rate trends and interest rate forecasts published by major financial institutions. The tools Apria may utilize to moderate its exposure to fluctuations in the relevant interest rate indices include, but are not limited to: (1) strategic determination of repricing periods and related principal amounts, and (2) derivative financial instruments such as interest rate swap agreements, caps or collars. Apria does not use derivative financial instruments for trading or other speculative purposes.

During 2006, Apria had two interest rate swap agreements in effect to fix its LIBOR-based variable rate debt. One of the agreements, which expired in December 2006, had a notional amount of \$25.0 million and a fixed rate of 3.42%. The other agreement, a forward-starting contract with a three-year term, became effective in January 2006, and has a notional amount of \$25.0 million that fixes an equivalent amount of the company's variable rate debt at 4.44%.

In 2005, Apria had two interest rate swap agreements. Each agreement had a notional amount of \$25.0 million, with one agreement expiring in December 2005 and the other agreement expiring in December 2006. In 2004, Apria also had two swap agreements with an aggregate notional amount of \$50.0 million that expired in December 2004.

The swap agreements are being accounted for as cash flow hedges under SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities." Accordingly, the difference between the interest received and interest paid is reflected as an adjustment to interest expense. For the years ended December 31, 2006, 2005 and 2004, Apria received (paid) net settlement amounts of \$540,000, \$11,000 and (\$1,381,000), respectively. At December 31, 2006, the aggregate fair value of the swap agreements was an asset of \$356,000 and is reflected in the accompanying consolidated balance sheets in other assets. Unrealized gains and losses on the fair value of the swap agreements are reflected, net of taxes, in operating income, as the transactions no longer qualify for hedge accounting treatment. Apria's exposure to credit loss under the swap agreement is limited to the interest rate spread in the event of counterparty nonperformance. Apria does not anticipate losses due to counterparty nonperformance as its counterparties to the swap agreement are nationally recognized financial institutions with strong credit ratings.

TREASURY STOCK

All repurchased shares of common stock are held as treasury shares.

In 2006, 7,672 shares of employee restricted stock shares, valued at \$141,000, were retained by the company upon vesting to satisfy the related tax obligation.

In October 2005, Apria's Board of Directors authorized the company to repurchase up to \$250.0 million worth of its outstanding common stock. On November 7, 2005, Apria purchased 7.3 million shares of its common stock for \$175.0 million through an accelerated share repurchase program. Under the agreement, Apria's

counterparty borrowed shares that were sold to Apria at an initial price of \$23.83. The counterparty then repurchased shares over a period that commenced immediately after the sale of shares to Apria. The repurchase transaction was completed in February 2006. The agreement contained a provision that subjected Apria to a purchase price adjustment based on the volume weighted average price of the company's common stock over the period during which the counterparty purchased the shares. Such provision resulted in an additional \$242,000 owed to the counterparty that Apria elected to settle in cash in February 2006. This amount was recorded as a liability at December 31, 2005, with a corresponding charge to interest expense reflecting the change in the fair value of the settlement contract. The amount remaining on the aforementioned Board authorization expires at the end of the first quarter of 2007.

In January 2004, Apria prepaid \$50.0 million to repurchase 1.7 million shares of its common stock at a strike price of \$28.89 through an accelerated share repurchase program. The repurchase of the shares was completed in April 2004 and the share price differential was settled in cash in June 2004, for a total cost of \$53 million. During the third quarter of 2004, the company purchased an additional 1.7 million shares for \$47.0 million.

BUSINESS COMBINATIONS

Apria periodically acquires complementary businesses in specific geographic markets. Because of the potential for a higher gross margin, Apria targets respiratory therapy businesses. These transactions are accounted for as purchases and the results of operations of the acquired companies are included in the accompanying statements of operations from the dates of acquisition. In accordance with SFAS No. 142, goodwill is no longer being amortized. Covenants not to compete are being amortized over the life of the respective agreements. Trade names and customer lists are being amortized over the period of their expected benefit.

In 2006, Apria closed 3 small acquisitions for an aggregate consideration of \$3.6 million. Allocation of this amount includes \$2.0 million to patient service equipment, \$1.3 million in customer lists and \$97,000 to goodwill. The aggregate consideration for the 21 acquisitions that closed during 2005 was \$103.0 million and \$148.7 million for the 27 acquisitions executed in 2004. Cash paid for acquisitions, which includes amounts deferred from prior year acquisitions, totaled \$8.1 million, \$105.5 million and \$144.2 million in 2006, 2005 and 2004, respectively.

Off-Balance Sheet Arrangements

Apria is not a party to off-balance sheet arrangements as defined by the Securities and Exchange Commission. However, from time to time the company enters into certain types of contracts that contingently require the company to indemnify parties against third-party claims. The contracts primarily relate to: (i) certain asset purchase agreements, under which the company may provide customary indemnification to the seller of the business being acquired; (ii) certain real estate leases, under which the company may be required to indemnify property owners for environmental and other liabilities, and other claims arising from the company's use of the applicable premises; and (iii) certain agreements with the company's officers, directors and employees, under which the company may be required to indemnify such persons for liabilities arising out of their relationship with the company.

The terms of such obligations vary by contract and in most instances a specific or maximum dollar amount is not explicitly stated therein. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, no liabilities have been recorded for these obligations on the company's balance sheets for any of the periods presented.

Quantitative and Qualitative Disclosures About Market Risk

Apria is exposed to interest rate fluctuations on its underlying variable rate long-term debt. Apria utilizes interest rate swap agreements to moderate such exposure. Apria does not use derivative financial instruments for trading or other speculative purposes.

At December 31, 2006, Apria's revolving credit facility borrowings totaled \$235.0 million. The bank credit agreement governing the revolver provides interest rate options based on the following indices: Federal Funds Rate, the Bank of America prime rate or the London Interbank Offered Rate, or LIBOR and all such interest rate options are subject to the application of an interest margin as specified in the bank credit agreement. At December 31, 2006, all of Apria's outstanding revolving debt was tied to LIBOR. See Item 7 — "Management's Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources — Long Term Debt."

During 2006, Apria had two interest rate swap agreements in effect to fix its LIBOR-based variable rate debt. One of the agreements, which expired in December 2006, had a notional amount of \$25.0 million and a fixed rate of 3.42%. The other agreement, a forward-starting contract with a three-year term, became effective in January 2006, and has a notional amount of \$25.0 million that fixes an equivalent amount of the company's variable rate debt at 4.44%. See Item 7 — "Management's Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources — Long Term Debt — Hedging Activities."

Based on the revolving debt outstanding and the swap agreements in place at December 31, 2006, a 100 basis point change in the applicable interest rates would increase or decrease Apria's annual cash flow and pretax earnings by approximately \$2.1 million. See "Management's Discussion and Analysis of Financial Condition and Results of Operations — Long-term Debt — Hedging Activities."

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

MARKET FOR THE REGISTRANT'S COMMON EQUITY

Apria's common stock is traded on the New York Stock Exchange under the symbol "AHG." The following table presents information on the range of high and low sales prices per share of Apria common stock since January 1, 2005 for the quarterly periods indicated:

	High	Low
Year ended December 31, 2006		
First quarter	\$24.76	\$21.69
Second quarter.....	22.92	17.37
Third quarter.....	22.95	17.38
Fourth quarter.....	27.70	19.25
Year ended December 31, 2005		
First quarter	\$33.56	\$29.78
Second quarter.....	36.75	29.05
Third quarter.....	35.55	31.56
Fourth quarter.....	32.84	20.51

As of February 23, 2007, there were 316 holders of record of Apria common stock. Apria has not declared or paid cash dividends on its common stock. While Apria regularly assess its dividend policy, we have no current plans to declare a dividend. Earnings and other cash resources will continue to be used in the expansion of our business.

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Apria Healthcare Group Inc.
Lake Forest, California

We have audited the accompanying consolidated balance sheets of Apria Healthcare Group, Inc. and subsidiaries (the “Company”) as of December 31, 2006 and 2005, and the related consolidated statements of income, stockholders’ equity and comprehensive income, and cash flows for each of the three years in the period ended December 31, 2006. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of Apria Healthcare Group, Inc. and subsidiaries at December 31, 2006 and 2005, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2006, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of the Company’s internal control over financial reporting as of December 31, 2006, based on the criteria established in *Internal Control—Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 1, 2007 expressed an unqualified opinion on management’s assessment of the effectiveness of the Company’s internal control over financial reporting and an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

As discussed in Note 7 to the consolidated financial statements, the Company changed its method of accounting for share based payments effective January 1, 2006, to conform to Statement of Financial Accounting Standards No. 123(R), *Share-Based Payment* and prospectively adjusted the 2006 financial statements for the change. Also as discussed in Note 2 to the consolidated financial statements, the Company changed its method of evaluating misstatements effective for fiscal years ending after November 15, 2006, to conform to Staff Accounting Bulletin No. 108, *Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements*.



Costa Mesa, California
March 1, 2007

Consolidated Balance Sheets

December 31,

(in thousands, except share data)	2006	2005
ASSETS		
Current Assets		
Cash and cash equivalents.....	\$ 14,657	\$ 23,304
Accounts receivable, less allowance for doubtful accounts of \$27,324 and \$41,527 at December 31, 2006 and 2005, respectively.....	211,097	226,478
Inventories, net.....	40,681	42,571
Deferred income taxes	36,648	30,916
Deferred expenses.....	22,712	–
Prepaid expenses and other current assets.....	19,142	20,732
TOTAL CURRENT ASSETS	344,937	344,001
PATIENT SERVICE EQUIPMENT, less accumulated depreciation of \$445,608 and \$446,728 at December 31, 2006 and 2005, respectively.....	212,068	225,575
PROPERTY, EQUIPMENT AND IMPROVEMENTS, NET	52,975	46,087
DEFERRED INCOME TAXES	–	4,059
GOODWILL	539,187	540,985
INTANGIBLE ASSETS, NET.....	6,551	10,580
DEFERRED DEBT ISSUANCE COSTS, NET	4,612	5,248
OTHER ASSETS	8,166	9,363
	\$1,168,496	\$1,185,898
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current Liabilities		
Accounts payable.....	\$ 66,969	\$ 63,984
Accrued payroll and related taxes and benefits	46,532	51,167
Income taxes payable	10,793	8,664
Other accrued liabilities.....	44,804	42,511
Deferred revenue	32,280	–
Current portion of long term debt.....	2,145	4,465
TOTAL CURRENT LIABILITIES.....	203,523	170,791
LONG TERM DEBT, net of current portion.....	485,000	640,855
DEFERRED INCOME TAXES	60,815	38,079
OTHER NON-CURRENT LIABILITIES.....	8,727	9,009
TOTAL LIABILITIES	758,065	858,734
COMMITMENTS AND CONTINGENCIES (Notes 10 and 12)		
STOCKHOLDERS' EQUITY		
Preferred stock, \$.001 par value: 10,000,000 shares authorized; none issued.....	–	–
Common stock, \$.001 par value: 150,000,000 shares authorized; 59,762,307 and 59,215,749 shares issued at December 31, 2006 and 2005, respectively; 42,789,450 and 42,250,564 outstanding at December 31, 2006 and 2005, respectively.....	60	59
Additional paid in capital	482,123	468,099
Treasury stock, at cost; 16,972,857 and 16,965,185 shares at December 31, 2006 and 2005, respectively.....	(429,573)	(429,432)
Retained earnings.....	357,470	287,982
Accumulated other comprehensive income	351	456
TOTAL STOCKHOLDERS' EQUITY.....	410,431	327,164
	\$1,168,496	\$1,185,898

See notes to consolidated financial statements.

Consolidated Statements of Income

	Year Ended December 31,		
(in thousands, except per share data)	2006	2005	2004
Net revenues:			
Fee for service arrangements	\$1,355,818	\$1,327,777	\$1,312,269
Capitation arrangements	161,489	146,324	139,180
TOTAL NET REVENUES	1,517,307	1,474,101	1,451,449
Costs and expenses:			
Cost of net revenues:			
Product and supply costs	345,552	309,413	271,723
Patient service equipment depreciation	113,177	111,759	119,391
Respiratory therapy services	38,501	34,669	–
Nursing services	8,825	9,078	10,644
Other	15,384	14,369	15,686
TOTAL COST OF NET REVENUES	521,439	479,288	417,444
Provision for doubtful accounts	38,723	46,948	48,567
Selling, distribution and administrative	804,365	792,177	777,671
<i>Qui tam</i> settlement and related costs (Note 12)	–	19,258	–
Amortization of intangible assets	5,080	6,941	6,712
TOTAL COSTS AND EXPENSES	1,369,607	1,344,612	1,250,394
OPERATING INCOME	147,700	129,489	201,055
Interest expense	31,205	22,972	20,799
Interest income	(1,742)	(853)	(779)
Write-off of deferred debt issuance costs	–	–	2,730
INCOME BEFORE TAXES	118,237	107,370	178,305
Income tax expense	43,257	40,429	64,297
NET INCOME	\$ 74,980	\$ 66,941	\$ 114,008
Basic net income per common share	\$ 1.77	\$ 1.39	\$ 2.31
Diluted net income per common share	\$ 1.75	\$ 1.37	\$ 2.27

See notes to consolidated financial statements.

Consolidated Statements of Stockholders' Equity and Comprehensive Income

(in thousands)	Common Stock		Additional Paid-In Capital	Treasury Stock		(Accumulated Deficit) Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Total Stockholders' Equity
	Shares	Par Value		Shares	Cost			
Balance at December 31, 2003	57,317	\$ 57	\$414,220	6,210	\$(154,432)	\$107,033	\$(930)	\$ 365,948
Exercise of stock options	893	1	18,314					18,315
Tax benefits related to stock options			2,587					2,587
Compensatory stock options and awards.....	26		4,423					4,423
Repurchases of common stock.....				3,418	(100,000)			(100,000)
Unrealized gain on interest rate swap agreements, net of taxes.....							904	904
Net income.....						114,008		114,008
Total comprehensive income						114,008	904	114,912
Balance at December 31, 2004.....	58,236	\$ 58	\$439,544	9,628	\$(254,432)	\$221,041	\$ (26)	\$ 406,185
Exercise of stock options	937	1	21,179					21,180
Tax benefits related to stock options			4,117					4,117
Compensatory stock options and awards.....	43		3,259					3,259
Repurchases of common stock.....				7,337	(175,000)			(175,000)
Unrealized gain on interest rate swap agreements, net of taxes.....							482	482
Net income.....						66,941		66,941
Total comprehensive income						66,941	482	67,423
Balance at December 31, 2005.....	59,216	\$ 59	\$468,099	16,965	\$(429,432)	\$287,982	\$ 456	\$ 327,164
Cumulative effect adjustment pursuant to adoption of SAB No. 108						(5,492)		(5,492)
Exercise of stock options	508	1	8,244					8,245
Tax benefits related to stock options			17					17
Compensatory stock options and awards.....	38		5,763					5,763
Restricted stock retained in treasury upon vesting.....				8	(141)			(141)
Unrealized loss on interest rate swap agreements, net of taxes.....							(105)	(105)
Net income.....						74,980		74,980
Total comprehensive income						74,980	(105)	74,875
Balance at December 31, 2006.....	59,762	\$ 60	\$482,123	16,973	\$(429,573)	\$357,470	\$ 351	\$ 410,431

See notes to consolidated financial statements.

Consolidated Statements of Cash Flows

Year Ended December 31,

(in thousands)	2006	2005	2004
OPERATING ACTIVITIES			
Net income.....	\$ 74,980	\$ 66,941	\$114,008
Items included in net income not requiring cash:			
Provision for doubtful accounts	38,723	46,948	48,567
Depreciation.....	133,563	133,677	140,762
Amortization of intangible assets	5,080	6,941	6,712
Amortization of deferred debt issuance costs	1,755	1,729	5,153
Deferred income taxes	24,673	(5,210)	20,798
Share-based compensation	5,762	3,259	4,423
Loss on disposition of assets and other	(81)	–	(682)
Changes in operating assets and liabilities, exclusive of effects of acquisitions:			
Accounts receivable.....	(23,342)	(54,198)	(70,302)
Inventories, net.....	2,025	(561)	(9,372)
Prepaid expenses and other assets.....	7,094	3,451	832
Accounts payable, exclusive of book cash overdraft.....	7,717	2,907	1,050
Accrued payroll and related taxes and benefits	(4,775)	3,547	4,308
Income taxes payable	2,145	(6,427)	7,935
Excess tax benefits from share-based compensation	(403)	–	–
Deferred revenue, net of related expenses	560	–	–
Accrued expenses.....	5,438	3,295	(2,577)
NET CASH PROVIDED BY OPERATING ACTIVITIES	280,914	206,299	271,615
INVESTING ACTIVITIES			
Purchases of patient service equipment and property, equipment and improvements, exclusive of effects of acquisitions	(125,628)	(118,867)	(137,358)
Proceeds from disposition of assets.....	778	767	211
Cash paid for acquisitions, including payments of deferred consideration	(8,082)	(105,471)	(144,235)
NET CASH USED IN INVESTING ACTIVITIES.....	(132,932)	(223,571)	(281,382)
FINANCING ACTIVITIES			
Proceeds from revolving credit facilities	29,800	216,250	250,850
Payments on revolving credit facilities.....	(184,800)	(51,000)	(26,100)
Payments on term loans	–	–	(244,063)
Payments on other long-term debt.....	(7,030)	(7,854)	(9,033)
Change in book cash overdraft included in accounts payable.....	(2,128)	(2,384)	1,419
Capitalized debt issuance costs.....	(1,119)	(15)	(2,775)
Repurchases of common stock.....	–	(175,000)	(100,000)
Excess tax benefits from share-based compensation	403	–	–
Issuances of common stock	8,245	21,180	18,315
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(156,629)	1,177	(111,387)
NET DECREASE IN CASH AND CASH EQUIVALENTS.....	(8,647)	(16,095)	(121,154)
Cash and cash equivalents at beginning of year	23,304	39,399	160,553
CASH AND CASH EQUIVALENTS AT END OF YEAR.....	\$ 14,657	\$ 23,304	\$ 39,399

SUPPLEMENTAL DISCLOSURES — See Note 6 and Note 8 for cash paid for interest and income taxes, respectively.

NON-CASH TRANSACTIONS — See Statements of Stockholders' Equity, Note 4 and Note 10 for tax benefit from stock option exercises, non-cash treasury stock transaction, liabilities assumed in acquisitions and purchase of property and equipment under capital leases, respectively.

Purchases of patient service equipment and property, equipment and improvements exclude purchases that remain unpaid at the end of the respective year. Such amounts are then included in the following year's purchases. Unpaid purchases were \$8,152, \$10,754 and \$10,895 at December 31, 2006, 2005 and 2004, respectively.

See notes to consolidated financial statements.

Notes to Consolidated Financial Statements

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation: The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. These statements include the accounts of Apria Healthcare Group Inc. (“Apria” or “the company”) and its subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation.

Company Background and Segment Reporting: Apria operates in the home healthcare segment of the healthcare industry, providing a variety of clinical services and related products and supplies as prescribed by a physician or authorized by a case manager as part of a care plan. Essentially all products and services offered by the company are provided through the company’s network of approximately 475 branch facilities, which are located throughout the United States and are currently organized into three geographic divisions. The company’s chief operating decision maker evaluates operating results on a divisional basis and, therefore, each division is designated an operating segment (previously company’s 15 regions). All divisions provide the same products and services, including respiratory therapy, infusion therapy and home medical equipment and supplies. For financial reporting purposes, all of the company’s operating segments are aggregated into one reportable segment in accordance with the aggregation criteria of Statement of Financial Accounting Standards (“SFAS”) No. 131, “Disclosures about Segments of an Enterprise and Related Information.”

Use of Accounting Estimates: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Revenue Recognition and Concentration of Credit Risk: Revenues are recognized on the date services and related products are provided to patients and are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including private insurers, prepaid health plans, Medicare and Medicaid. For the years 2006, 2005 and 2004, revenues reimbursed under arrangements with Medicare and Medicaid were approximately 36%, 39% and 38%, respectively, as a percentage of total revenues. In all three years presented, no other third-party payor group represented more than 9% of the company’s revenues. The majority of the company’s revenues are derived from fees charged for patient care under fee-for-service arrangements. Revenues derived from capitation arrangements represented 11% of total net revenues for 2006 and less than 10% of total net revenues for 2005 and 2004. Capitation revenue is earned as a result of entering into a contract with a third party to provide its members certain services without regard to the actual services provided, therefore revenue is recognized in the period that the beneficiaries are entitled to healthcare services.

Cash and Cash Equivalents: Apria maintains cash with various financial institutions. These financial institutions are located throughout the United States and the company’s cash management practices limit exposure to any one institution. Outstanding checks, which are reported as a component of accounts payable, were \$18,519,000 and \$20,647,000 at December 31, 2006 and 2005, respectively. Management considers all highly liquid instruments purchased with a maturity of less than three months to be cash equivalents.

Accounts Receivable: Included in accounts receivable are earned but unbilled receivables of \$30,036,000 and \$39,015,000 at December 31, 2006 and 2005, respectively. Delays ranging from a day up to several weeks between the date of service and billing can occur due to delays in obtaining certain required payor-specific documentation from internal and external sources. Earned but unbilled receivables are aged from date of service and are considered in Apria’s analysis of historical performance and collectibility.

Due to the nature of the industry and the reimbursement environment in which Apria operates, certain estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement

amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim denial or account review.

Management performs periodic analyses to evaluate accounts receivable balances to ensure that recorded amounts reflect estimated net realizable value. Specifically, management considers historical realization data, accounts receivable aging trends, other operating trends, the extent of contracted business and business combinations. Also considered are relevant business conditions such as governmental and managed care payor claims processing procedures and system changes. Additionally, focused reviews of certain large and/or problematic payors are performed. Due to continuing changes in the healthcare industry and third-party reimbursement, it is possible that management's estimates could change in the near term, which could have an impact on operations and cash flows.

Accounts receivable are reduced by an allowance for doubtful accounts which provides for those accounts from which payment is not expected to be received, although services were provided and revenue was earned. Upon determination that an account is uncollectible, it is written-off and charged to the allowance.

Inventories: Inventories are stated at the lower of cost (first-in, first-out method) or market and consist primarily of pharmaceuticals and items used in conjunction with patient service equipment.

Patient Service Equipment: Patient service equipment is stated at cost and consists of medical equipment provided to in-home patients. Depreciation is provided using the straight-line method over the estimated useful lives of the equipment, which range from one to ten years.

Property, Equipment and Improvements: Property, equipment and improvements are stated at cost. Included in property and equipment are assets under capitalized leases which consist of information systems hardware and software. Depreciation is provided using the straight-line method over the estimated useful lives of the assets. Estimated useful lives for each of the categories presented in Note 3 are as follows: leasehold improvements — the shorter of the remaining lease term or seven years; equipment and furnishings — three to fifteen years; and information systems — three to six years.

Capitalized Software: Included in property, equipment and improvements are costs related to internally developed and purchased software that are capitalized and amortized over periods not exceeding five years. Capitalized costs include direct costs of materials and services incurred in developing or obtaining internal-use software and payroll and benefit costs for employees directly involved in the development of internal-use software.

Long-Lived Assets: The recoverability of long-lived assets, including property and equipment and certain identifiable intangible assets, is evaluated in accordance with SFAS 144, "Accounting for the Impairment or Disposal of Long-Lived Assets." SFAS 144 requires the company to review for impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Factors considered important which could trigger an impairment review include:

- ▶ significant underperformance relative to historical or projected future operating results;
- ▶ significant changes in the manner of use of the assets or the strategy for our overall business;
- ▶ significant decrease in the market value of the assets; and
- ▶ significant negative industry or economic trends.

When it is determined that the carrying amount of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators, management assesses the assets for impairment based on the estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment loss is recorded for the excess of the asset's carrying amount over its fair value. Fair value is generally determined based on the estimated future discounted cash flows over the remaining useful life of the asset using a discount rate determined by management to be commensurate with the risk inherent in the company's current business model. The assumptions supporting the cash flows, including the discount rates, are determined using management's best estimates as of the date of the impairment review. If these estimates or their related

assumptions change in the future, the company may be required to record additional impairment charges for these assets, and future results of operations could be adversely affected.

Goodwill: Goodwill arising from business combinations represents the excess of the purchase price over the estimated fair value of the net assets of the businesses acquired. In accordance with the provisions of SFAS No. 142, "Goodwill and Other Intangible Assets," goodwill is not amortized but tested annually for impairment or more frequently if circumstances indicate the possibility of impairment. Management does not believe any impairment of its goodwill existed at December 31, 2006.

Intangible Assets: Intangible assets consist of covenants not to compete, tradenames and customer lists, all of which arose from business combinations. The values assigned to the covenants are amortized on a straight-line basis over their contractual terms, which range from three to five years. The customer list and tradename valuations are amortized over their period of expected benefit, which averages 9 months and 24 months, respectively. Management tests for impairment in accordance with SFAS No. 142.

Deferred Debt Issuance Costs: Apria capitalizes debt issuance costs which include those associated with its revolving credit facility and the convertible senior notes. Such costs are classified as non-current assets. Costs relating to the revolving credit facility are being amortized through the maturity date of June, 2011. Costs relating to the convertible senior notes are amortized from the issuance date through September, 2008. See Note 6 — "Long-term Debt."

Fair Value of Financial Instruments: The carrying value of Apria's bank debt approximates fair value because the underlying instruments are variable notes that reprice frequently. The fair value of the convertible senior notes, as determined by reference to quoted market prices, is \$242,398,000 and \$240,625,000 at December 31, 2006 and 2005, respectively. The carrying amounts of cash and cash equivalents, accounts receivable, trade payables and accrued expenses approximate fair value due to their short maturity.

Respiratory Therapy Expenses: Respiratory therapy expenses presented within cost of net revenues are comprised primarily of employee salary and benefit costs or contract fees paid to respiratory therapists and other related professionals who are deployed to service a patient. Apria's respiratory therapy personnel are also engaged in a number of administrative and marketing tasks, and accordingly, these costs are classified within selling, distribution and administrative expenses and amounted to \$15,694,000 in 2006 and \$18,807,000 in 2005.

Apria adopted the classification described above in 2005. During prior years, the data was not captured in the detail necessary to make a corresponding reclassification. Therefore, all respiratory therapy expenses for 2004 are classified within selling, distribution and administrative expenses and totaled \$50,004,000.

Nursing Expenses: Nursing expenses presented within cost of net revenues are comprised primarily of employee salary and benefit costs, as well as fees paid to contracted workers who are deployed to service a patient. The majority of these costs relate to the company's infusion therapy service line which were previously classified as selling, distribution and administrative expenses. Additional nursing costs that are currently, and were previously, presented within the cost of net revenues relate to a small ancillary nursing service business that generates approximately \$1,000,000 in revenue annually.

Apria adopted the classification described above in 2005. Certain nursing expenses incurred by the infusion therapy business, including administrative and marketing costs, remain within selling, distribution and administrative expenses and totaled \$4,000,000, \$3,948,000 and \$4,189,000 for 2006, 2005 and 2004, respectively.

Distribution Expenses: Distribution expenses are included in selling, distribution and administrative expenses and totaled \$174,273,000, \$171,724,000 and \$157,142,000 in 2006, 2005, and 2004, respectively. Such expense represents the cost incurred to deliver product to the end user. Included are leasing, maintenance, licensing and fuel costs associated with the company's vehicle fleet; salaries and other costs related to drivers and dispatch personnel; and amounts paid to courier and other outside shipping vendors. Such expenses fall within the definition of "shipping and handling" costs as discussed in Emerging Issues Task Force No. 00-10 "Accounting for Shipping and Handling Fees and Costs," which permits their income statement classification within selling and administrative expenses.

Self-Insurance: Apria is self-insured for certain employee medical claims and benefits, as well as workers' compensation, vehicle liability, professional and general liability coverages. Accruals for medical claims at December 31, 2006 and 2005 were \$10,061,000 and \$7,239,000, respectively. Amounts accrued for costs of the other liability coverages totaled \$10,977,000 and \$11,763,000 at December 31, 2006 and 2005, respectively. All such amounts are classified in other accrued liabilities.

Advertising: Advertising costs are initially established as a prepaid expense and amortized over the period of expected benefit. Such expenses are included in selling, distribution and administrative expenses and amounted to \$5,849,000, \$6,844,000 and \$4,799,000 for 2006, 2005 and 2004, respectively.

Income Taxes: Apria provides for income taxes in accordance with provisions specified in SFAS No. 109, "Accounting for Income Taxes." Accordingly, deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities. These differences will result in taxable or deductible amounts in the future, based on tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to amounts that are more likely than not to be realized.

Derivative Instruments and Hedging Activities: From time to time Apria uses derivative financial instruments to limit exposure to interest rate fluctuations on the company's variable rate long-term debt. The company accounts for derivative instruments pursuant to the provisions of SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities." The company's derivatives are recorded on the balance sheet at their fair value and, for derivatives accounted for as cash flow hedges, any unrealized gains or losses on their fair value are included, net of tax in operating income.

Share-Based Compensation: Prior to 2006, the company accounted for its stock-based compensation plans under the recognition and measurement principles of Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees," and related interpretations. For 2005 and 2004, net income reflects compensation expense for restricted stock awards and restricted stock purchase rights valued in accordance with APB No. 25.

Apria adopted the provisions of SFAS No. 123R, "Share-Based Payment" on January 1, 2006. The company elected to employ the modified prospective transition method and, accordingly, financial statement amounts for prior periods presented have not been restated to reflect the fair value method of expensing share-based compensation. The company elected to use the short-cut method, as provided by SFAS No. 123R, for determining the historical pool of tax benefits. See "Note 7 — Share-Based Compensation and Stockholders' Equity."

Comprehensive Income: For the years ended December 31, 2006, 2005 and 2004, the difference between net income and comprehensive income is \$(105,000), \$482,000 and \$904,000, respectively, net of taxes, which is attributable to unrealized (losses) and gains on various interest rate swap agreements.

Per Share Amounts: Basic net income per share is computed by dividing net income available to common stockholders by the weighted-average number of common shares outstanding. Diluted net income per share includes the effect of the potential shares outstanding, including dilutive stock options and other awards, using the treasury stock method.

NOTE 2 — RECENT ACCOUNTING PRONOUNCEMENTS

In December 2004, the FASB issued SFAS No. 123R, "Share-Based Payment." This statement replaces SFAS No. 123, "Accounting for Stock-Based Compensation," and supersedes APB Opinion No. 25, "Accounting for Stock Issued to Employees." SFAS No. 123R requires a company to measure the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of the award. The cost is recognized over the period during which the employee is required to provide service in exchange for the award (usually the vesting period). Apria adopted the statement January 1, 2006. See "Note 7 — Share-Based Compensation."

In May 2005, the FASB issued SFAS No. 154, “Accounting Changes and Error Corrections,” which replaces APB Opinion No. 20, “Accounting Changes,” and FASB Statement No. 3, “Reporting Accounting Changes in Interim Financial Statements.” SFAS No. 154 changes the accounting for, and the reporting of, a change in accounting principle. The statement also defines and requires retrospective application of a change in accounting principle to prior periods’ financial statements unless impracticable. If retrospective application is impracticable, the new accounting principle must be applied to the asset and liability balances as of the beginning of the earliest period practicable and a corresponding adjustment to the opening balance of retained earnings for the same period, rather than being reported in the income statement. Additionally, SFAS No. 154 addresses a change in accounting for estimates effected by a change in accounting principle and redefines restatement as a revision to reflect the correction of an error. The statement is effective for accounting changes and error corrections made in fiscal years beginning after December 15, 2005. Accordingly, Apria adopted the statement January 1, 2006. The adoption of SFAS No. 154 did not have a material effect on the company’s consolidated financial statements.

In February 2006, the FASB issued SFAS No. 155, “Accounting for Certain Hybrid Financial Instruments.” The statement amends SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities” and SFAS No. 140, “Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities.” The statement is effective for all financial instruments acquired or issued after the beginning of an entity’s first fiscal year that begins after September 15, 2006. Accordingly, the company adopted SFAS No. 155 on January 1, 2007. Such adoption did not have a material effect on the company’s consolidated financial statements.

In June 2006, the FASB issued Interpretation No. 48 (“FIN No. 48”), Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statement No.109, Accounting for Income Taxes. This standard creates a comprehensive model to address accounting for uncertainty in tax positions. FIN No. 48, clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized for financial statements. FIN No. 48 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The adoption of FIN No. 48 is required for fiscal periods beginning after December 15, 2006. The company adopted FIN No. 48 as of January 1, 2007 and estimates that it will record a cumulative effect adjustment of a range of approximately \$3,000,000 to \$5,000,000 to increase its uncertain tax positions accrual. This estimated cumulative effect adjustment will be charged to opening retained earnings.

In September 2006, The FASB issued SFAS No. 157, “Fair Value Measurements,” which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. The statement is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. Management is currently evaluating the statement to determine what, if any, impact it will have on the company’s consolidated financial statements.

In September 2006, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 108 (“SAB No. 108”), “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,” which provides guidance on quantifying financial statement misstatements. SAB No. 108 was issued in order to eliminate the diversity of practice surrounding how public companies quantify financial statement misstatements. SAB No. 108 is effective for annual financial statements covering the first fiscal year ending after November 15, 2006.

Traditionally, there have been two widely recognized methods for quantifying the effects of financial statement misstatements: the “roll-over” method and the “iron curtain” method. The roll-over method focuses primarily on the impact of a misstatement on the income statement, including the reversing effect of prior year misstatements, but its use can lead to the accumulation of misstatements in the balance sheet. The iron-curtain method, on the other hand, focuses primarily on the effect of correcting the period-end balance sheet with less emphasis on the reversing effects of prior year errors on the income statement. Prior to Apria’s application of the guidance in SAB No. 108, Apria management used the roll-over method for quantifying financial statement misstatements.

In SAB No. 108, the SEC staff established an approach that requires quantification of financial statement misstatements based on the effects of the misstatements on each of the company's financial statements and the related financial statement disclosures. This model is commonly referred to as a "dual approach" because it requires quantification of errors under both the iron curtain and the roll-over methods.

SAB No. 108 permits existing public companies to initially apply its provisions either by (i) restating prior financial statements as if the "dual approach" had always been applied or (ii) recording the cumulative effect of initially applying the "dual approach" as adjustments to the carrying values of assets and liabilities with an offsetting adjustment recorded to the opening balance of retained earnings. Apria elected to record the effects of applying SAB No. 108 using the cumulative effect transition method. The misstatement that has been corrected is described below.

Approximately 50% of Apria's net revenues are derived from rental arrangements to provide respiratory and other home medical equipment to patients in the home. Apria bills for these services on a monthly basis. The initial billing and revenue recognition is generated upon proper qualification of the patient and confirmation of delivery. Subsequent billings are processed monthly until the period of medical necessity ends. As a matter of process, Apria generates the subsequent billings in 30-day cycles so that each month's billing falls on approximately the same day of the month as the initial billing. Prior to application of SAB No. 108, rental revenue was recognized in the month of billing.

This accounting treatment resulted in an overstatement of rental revenue at a given month-end, as a portion of that revenue corresponding to the portion of the rental period that fell into the subsequent month, had not yet been earned. As a result of the revenue misstatement, the corresponding expenses were also recognized before actually incurred. Apria management previously quantified these errors under the roll-over method and concluded that they were immaterial.

In its application of SAB No. 108, Apria corrected the aforementioned errors by deferring unearned rental revenues and establishing a deferred revenue line item on its balance sheet. The corresponding expenses have been deferred through the establishment of a deferred expense line item. Such deferral of revenues and expenses also required adjustment to deferred income taxes. Apria adopted SAB No. 108 in the fourth quarter of 2006 and elected the cumulative effect transition method of application. Accordingly, Apria adjusted the carrying values of the applicable assets and liabilities with an offsetting adjustment to its opening balance of retained earnings. This correcting entry and the balance sheet line items that were affected are summarized in the following table:

(in thousands)	Adjustment Recorded as of December 31, 2006
Balance Sheet	
Deferred expenses	\$ 22,712
Deferred income tax liability.....	(8,867)
Deferred revenue	(32,280)
Deferred income tax asset	12,602
Retained earnings, beginning.....	5,492
Statement of Income	
Net revenues	\$ 466
Cost of net revenues.....	(22)
Selling, distribution and administrative expenses	(72)
Income before taxes	560
Income taxes.....	219
Net income.....	\$ 341

NOTE 3 — PROPERTY, EQUIPMENT AND IMPROVEMENTS

Property, equipment and improvements consist of the following:

(in thousands)	December 31,	
	2006	2005
Leasehold improvements.....	\$ 36,770	\$ 33,942
Equipment and furnishings.....	56,696	55,540
Information systems — hardware.....	88,396	77,559
Information systems — software.....	51,753	41,544
	233,615	208,585
Less accumulated depreciation	(180,640)	(162,498)
	\$ 52,975	\$ 46,087

Depreciation expense for property, equipment and improvements was \$20,387,000, \$21,918,000 and \$21,371,000 for 2006, 2005 and 2004, respectively.

NOTE 4 — BUSINESS COMBINATIONS

During 2006, Apria acquired three complementary businesses within specific geographic markets, comprised primarily of home respiratory therapy businesses. Similarly, the company acquired 21 companies during 2005 and 27 in 2004. For all periods presented, these all-cash transactions were accounted for as purchases and, accordingly, the results of operations of the acquired businesses are included in the consolidated income statements from the dates of acquisition. The purchase prices were allocated to the various underlying tangible and intangible assets and liabilities on the basis of estimated fair value.

The following table summarizes the allocation of the purchase prices of all acquisitions made by the company. Payments deferred from prior years totaled \$4,523,000, \$8,576,000 and \$4,646,000 for the years 2006, 2005 and 2004, respectively. At December 31, 2006, 2005 and 2004, outstanding deferred consideration totaled \$108,000, \$5,682,000 and \$8,575,000, respectively, and is included in the consolidated balance sheets in other accrued liabilities.

Cash paid (received) for acquisitions:

(in thousands)	Year Ended December 31,		
	2006	2005	2004
Fair value of patient service equipment acquired.....	\$ 1,923	\$ 7,453	\$ 9,880
Fair value of property and equipment acquired.....	4	985	1,995
Fair value of other assets acquired	641	1,577	2,712
Intangible assets	1,100	7,613	9,263
Goodwill	(1,112)	85,362	125,091
Total assets acquired	2,556	102,990	148,941
Liabilities assumed and accrued, net of payments deferred from prior years.....	5,526	2,481	(4,706)
Net assets acquired	\$ 8,082	\$105,471	\$144,235

The following supplemental unaudited *pro forma* information presents the combined operating results of Apria and the businesses that were acquired by Apria during 2006, 2005 and 2004, as if the acquisitions had occurred at the beginning of each of the periods presented. The *pro forma* information is based on the historical financial statements of Apria and those of the acquired businesses. Amounts are not necessarily indicative of the results that may have been attained had the combinations been in effect at the beginning of the periods presented or that may be achieved in the future.

(in thousands, except per share data)	Year Ended December 31,		
	2006	2005	2004
Net revenues.....	\$1,523,656	\$1,551,002	\$1,646,988
Net income.....	76,012	70,865	127,217
Basic net income per common share.....	\$ 1.79	\$ 1.47	\$ 2.58
Diluted net income per common share.....	\$ 1.77	\$ 1.45	\$ 2.54

NOTE 5 — GOODWILL AND INTANGIBLE ASSETS

Apria accounts for its business combinations in accordance with SFAS No. 141, “Business Combinations,” which requires that the purchase method of accounting be applied to all business combinations and addresses the criteria for initial recognition of intangible assets and goodwill. In accordance with SFAS No. 142, goodwill and other intangible assets with indefinite lives are not amortized but are tested for impairment annually, or more frequently if circumstances indicate the possibility of impairment. If the carrying value of goodwill or an intangible asset exceeds its fair value, an impairment loss shall be recognized.

Apria’s goodwill impairment test is conducted at a “reporting unit” level and compares each reporting unit’s fair value to its carrying value. The company has determined that its geographic divisions are reporting units under SFAS No. 142 (previously its regions). The measurement of fair value for each division is based on an evaluation of future discounted cash flows and is further tested using a multiple of earnings approach. For all years presented, Apria’s tests indicated that no impairment existed and, accordingly, no loss has been recognized.

For the year ended December 31, 2006, the net decrease in the carrying amount of goodwill of \$1,798,000 is the result of the write off of goodwill in the sale of a previously-acquired business back to the original seller; adjustments to preliminary acquisition valuations that resulted in goodwill decreases; and goodwill recorded from 2006 acquisitions. All of the goodwill recorded in conjunction with business combinations for the periods presented is expected to be deductible for tax purposes.

Intangible assets, all of which are subject to amortization, consist of the following:

(dollars in thousands)	Average Life in Years	December 31,			December 31,		
		2006			2005		
		Gross Carrying Amount	Accumulated Amortization	Net Book Value	Gross Carrying Amount	Accumulated Amortization	Net Book Value
Covenants not to compete.....	5.0	\$ 13,506	\$ (7,313)	\$ 6,193	\$ 16,352	\$ (6,316)	\$ 10,036
Tradenames.....	—	—	—	—	628	(440)	188
Customer lists.....	1.0	1,283	(925)	358	1,588	(1,232)	356
	3.6	\$ 14,789	\$ (8,238)	\$ 6,551	\$ 18,568	\$ (7,988)	\$ 10,580

Amortization expense amounted to \$5,080,000, \$6,941,000 and \$6,712,000 for the years 2006, 2005 and 2004, respectively. Estimated amortization expense for each of the fiscal years ending December 31, is presented below:

Year Ending December 31,	(in thousands)
2007.....	\$ 2,916
2008.....	2,066
2009.....	1,254
2010.....	315

NOTE 6 — LONG-TERM DEBT

Long-term debt consists of the following:

	December 31,	
(in thousands)	2006	2005
Notes payable relating to revolving credit facilities	\$ 235,000	\$ 390,000
Convertible senior notes.....	250,000	250,000
Capital lease obligations (see Note 10)	—	1,111
Other	2,145	4,209
	487,145	645,320
Less: current maturities	(2,145)	(4,465)
	\$485,000	\$640,855

Revolving Credit Facility: Apria's senior secured credit agreement with Bank of America and a syndicate of lenders was amended effective June 23, 2006. The amendment extended the maturity date from November 23, 2009 to June 23, 2011 and lowered the applicable interest rate margins and commitment fees.

The credit agreement is structured as a \$500 million revolving credit facility and permits Apria to select one of two variable interest rates. One option is the base rate, which is expressed as the higher of (a) the Federal Funds rate plus 0.50% or (b) the Bank of America prime rate. The other option is the Eurodollar rate, which is based on the London Interbank Offered Rate ("LIBOR"). Interest on outstanding balances under the credit agreement is determined by adding a margin to the Eurodollar rate or base rate in effect at each interest calculation date. The applicable margin for the revolving credit facility is based on Apria's debt rating as determined by either Standard and Poor's Ratings Services or Moody's Investor Services with respect to the credit facility.

The new applicable margins range from 0.625% to 1.25% for Eurodollar loans and from zero to 0.25% for base rate loans. The range for commitment fees on the unused portion of the revolving credit facility is now 0.10% to 0.20%. The effective interest rate at December 31, 2006, after consideration of the effect of the swap agreements, was 6.25%. Without the effect of the swap agreements, such rate would have been 6.35%.

At December 31, 2006, borrowings under the revolving credit facility were \$235,000,000, outstanding letters of credit totaled \$3,855,000 and credit available under the revolving facility was \$261,145,000. At December 31, 2006, the company was in compliance with all of the financial covenants required by the credit agreement. Borrowings under the credit facility are secured by a pledge of the common stock of all of the company's subsidiaries.

Convertible Senior Notes: In August 2003, Apria issued convertible senior notes in the aggregate principal amount of \$250,000,000 under an indenture between Apria and U.S. Bank National Association. The notes were issued in a private placement at an issue price of \$1,000 per note (100% of the principal amount at maturity) and were subsequently registered with the Securities and Exchange Commission. The notes will mature on September 1, 2033, unless earlier converted, redeemed or repurchased by Apria. Apria may redeem some or all of the notes at any time after September 8, 2010, at a redemption price equal to 100% of the principal amount of the notes to be redeemed plus accrued and unpaid interest and contingent interest, if any, to the redemption date. The holders of the notes may require Apria to repurchase some or all of the notes at a repurchase price equal to 100% of the principal amount of the notes plus accrued and unpaid interest, including contingent interest, up to but excluding the applicable repurchase date, initially on September 1, 2008, and subsequently on September 1 of 2010, 2013, 2018, 2023 and 2028, or at any time prior to their maturity following a fundamental change, as defined in the indenture. Any notes that Apria is required to repurchase will be paid for in cash, pursuant to the terms of a December 2004 amendment to the indenture which eliminated the company's option of paying part of the repurchase price in common stock.

The notes bear interest at the rate of 3 $\frac{3}{8}$ % per annum, which is payable on September 1 and March 1 of each year, beginning on March 1, 2004. Also, during certain periods commencing on September 8, 2010, Apria will pay contingent interest on the interest payment date for the applicable interest period if the average trading price

of the notes during the five trading days ending on the third day immediately preceding the first day of the applicable interest period equals or exceeds 120% of the principal amount of the notes. The contingent interest payable per note will equal 0.25% per year of the average trading price of such note during the applicable five trading-day reference period. Further, the notes are convertible, at the holders' option, during certain periods into shares of Apria common stock, initially at a conversion rate of 28.6852 shares of common stock per \$1,000 principal amount of notes, subject to adjustment and under certain circumstances as outlined in the indenture.

The notes are unsecured and unsubordinated obligations and are senior in right of payment to any subordinated debt of the company. The notes rank junior to the company's senior secured credit facility to the extent of the assets securing such indebtedness.

Maturities of long-term debt are as follows:

Year Ending December 31,	(in thousands)
2007.....	\$ 2,145
2008.....	—
2009.....	—
2010.....	—
2011.....	235,000
Thereafter.....	250,000
	\$487,145

Total interest paid on debt in 2006, 2005 and 2004 amounted to \$29,891,000, \$18,783,000 and \$18,090,000, respectively.

Hedging Activities: Apria is exposed to interest rate fluctuations on its underlying variable rate long-term debt. Apria's policy for managing interest rate risk is to evaluate and monitor all available relevant information, including but not limited to, the structure of its interest-bearing assets and liabilities, historical interest rate trends and interest rate forecasts published by major financial institutions. The tools Apria may utilize to moderate its exposure to fluctuations in the relevant interest rate indices include, but are not limited to: (1) strategic determination of repricing periods and related principal amounts, and (2) derivative financial instruments such as interest rate swap agreements, caps or collars. Apria does not use derivatives for trading or other speculative purposes.

During 2006, Apria had two interest rate swap agreements in effect to fix its LIBOR-based variable rate debt. One of the agreements, which expired in December 2006, had a notional amount of \$25,000,000 and a fixed rate of 3.42%. The other agreement, a forward-starting contract with a three-year term, became effective in January 2006, and has a notional amount of \$25,000,000 that fixes an equivalent amount of the company's variable rate debt at 4.44%.

In 2005, Apria had two interest rate swap agreements. Each agreement had a notional amount of \$25,000,000, with one agreement expiring in December 2005 and the other agreement expiring in December 2006. In 2004, Apria also had two swap agreements with an aggregate notional amount of \$50,000,000 that expired in December 2004.

The swap agreements are being accounted for as cash flow hedges under SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities." Accordingly, the difference between the interest received and interest paid is reflected as an adjustment to interest expense. For the years ended December 31, 2006, 2005 and 2004, Apria received (paid) net settlement amounts of \$540,000, \$11,000 and (\$1,381,000), respectively. At December 31, 2006 and 2005, the aggregate fair value of the swap agreements was an asset of \$356,000 and \$769,000, respectively, and is reflected in the accompanying consolidated balance sheets in other assets. Unrealized gains and losses on the fair value of the swap agreements are reflected, net of taxes, in operating income, as the transactions no longer qualify for hedge accounting treatment. Apria's exposure to credit loss under the swap agreement is limited to the interest rate spread in the event of counterparty nonperformance. Apria does not anticipate losses due to counterparty nonperformance as its counterparties to the swap agreement are nationally recognized financial institutions with strong credit ratings.

NOTE 7 — SHARE-BASED COMPENSATION AND STOCKHOLDERS' EQUITY

Effective January 1, 2006, Apria adopted the provisions of SFAS No. 123R, "Share-Based Payment," which establishes accounting for equity instruments exchanged for employee services. Under the provisions of SFAS No. 123R, share-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employee's requisite service period (generally the vesting period of the equity grant). Prior to January 1, 2006, the company accounted for share-based compensation to employees in accordance with APB No. 25, "Accounting for Stock Issued to Employees," and related interpretations. The company also followed the disclosure requirements of SFAS No. 123, "Accounting for Stock-Based Compensation," as amended by SFAS No. 148, "Accounting for Stock-Based Compensation — Transition and Disclosure." The company elected to employ the modified prospective transition method as provided by SFAS No. 123R and, accordingly, financial statement amounts for the prior periods presented have not been restated to reflect the fair value method of expensing share-based compensation.

For the year ended December 31, 2006, the company recorded share-based compensation expense of \$5,762,000, of which \$2,081,000 was related to awards issued prior to the adoption of SFAS No. 123R. All such compensation is reflected in the accompanying condensed consolidated income statement within the selling, distribution and administrative expense line item. The related awards were granted to administrative personnel or members of the company's Board of Directors and therefore no portion of the share-based compensation has been classified within cost of net revenues. Share-based compensation expense recognized in 2006 is based on awards ultimately expected to vest; therefore, it has been reduced for estimated forfeitures. SFAS No. 123R requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. In the *pro forma* information presented for periods prior to 2006, the company accounted for forfeitures as they occurred.

For the year ended December 31, 2006, Apria's adoption of SFAS No. 123R reduced the company's operating income and income before taxes by \$2,323,000 and net income was reduced by \$1,737,000. Basic and diluted earnings per share were each reduced by \$0.04 for the year ended December 31, 2006. The adoption of SFAS No. 123R did not affect cash flow.

For the year ended December 31, 2006, cash received from the exercise of options totaled \$8,245,000. Income tax benefits related to stock-based compensation arrangements amounted to \$17,000.

The company estimates the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, the expected option term, the expected volatility of the company's stock over the option's expected term, the risk-free interest rate over the option's term, and the company's expected annual dividend yield. Apria's management believes that the valuation technique and the approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of the company's stock options granted in 2006. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.

The key input assumptions that were utilized in the valuation of the stock options granted during the year ended December 31, 2006 are summarized in the table below.

Expected option term ¹	4.8 years
Expected volatility ²	27.3%
Risk-free interest rate ³	4.6%
Expected annual dividend yield.....	0%

¹ The expected option term is based on historical exercise and post-vesting termination patterns.

² Expected volatility represents a combination of historical stock price volatility and implied volatility from publicly-traded options on Apria's common stock.

³ The risk-free interest rate is based on the implied yield on a U.S. Treasury zero coupon issue with a remaining term equal to the expected term of the option.

2003 Performance Incentive Plan: In July 2003, Apria's shareholders approved the 2003 Performance Incentive Plan ("2003 Plan"), which permits the grant of stock options, stock appreciation rights ("SARs"), stock bonuses, restricted stock, performance stock, stock units, phantom stock, dividend equivalents, or similar rights to purchase or acquire shares, and cash awards. Any award may be paid or settled in cash. The 2003 Plan is currently the only plan from which stock-based awards may be granted.

The maximum number of shares that may be issued as awards under the 2003 Plan equals the sum of (1) 6,500,000 shares, plus (2) the number of shares subject to stock options granted under previous plans, which expire or are cancelled or terminated without being exercised, after the effective date of the 2003 Plan.

The 2003 Plan also contains the following limits:

- ▶ grants of incentive stock options up to 2,000,000 shares,
- ▶ grants of options and SARs during any calendar year to any individual up to 500,000 shares,
- ▶ shares subject to all awards granted to an individual during any calendar year up to 1,000,000 shares,
- ▶ awards granted to non-employee directors up to 700,000 shares,
- ▶ awards granted, other than for stock options and SARs, up to 2,275,000 shares,
- ▶ performance-based awards, other than stock options and SARs, granted to an individual up to 500,000 shares in a calendar year, and
- ▶ performance-based awards, payable in cash, granted to an individual up to \$10,000,000 in a calendar year.

The per share exercise price of an option or SAR (collectively referred to as “options”) generally may not be less than the per share fair market value on the date of grant. The maximum term of an option is ten years from the date of grant. Performance based awards may also be issued from the 2003 Plan. The vesting or payment of such awards will depend on the company’s performance to established measurement criteria. The performance measurement period may range from three months to ten years. Performance based awards may be paid in stock or in cash. The company has historically issued new shares when options or stock-based awards are exercised.

The company believes that share-based awards better align the interests of its senior management and other key employees with those of its shareholders as well as serving as an effective tool to attract, retain and motivate plan participants.

Stock Options: Apria’s incentive plan provides for the granting of stock options to employees and non-employee directors. Such grants to employees may include non-qualified and incentive stock options. The exercise price of an option is established at the fair market value of a share of Apria common stock on the date of grant. Vesting of stock options is time-based and is generally over a three-year period.

The following table summarizes the activity for stock options for the years ended December 31, 2004, 2005 and 2006:

	Options	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (in Years)	Aggregate Intrinsic Value
Outstanding at January 1, 2004.....	4,553,926	\$ 21.73		
Granted.....	1,647,000	31.45		
Exercised.....	(893,270)	20.90		
Forfeited.....	(193,511)	26.19		
Outstanding at December 31, 2004.....	5,114,145	\$ 24.84	7.37	\$ 41,774,469
Granted.....	49,000	32.45		
Exercised.....	(920,385)	22.49		
Forfeited.....	(166,055)	29.20		
Outstanding at December 31, 2005.....	4,076,705	\$ 25.28	6.60	\$ 7,881,252
Granted.....	1,056,000	23.23		
Exercised.....	(349,596)	20.64		
Forfeited.....	(726,795)	29.48		
Outstanding at December 31, 2006.....	4,056,314	\$ 24.59	6.38	\$ 13,750,742
Vested or expected to vest as of December 31, 2006.....	3,933,107	\$ 24.63	6.25	\$ 13,346,073
Exercisable at December 31, 2006.....	3,201,314	\$24.95	5.56	\$10,819,092

The weighted-average fair value of stock options granted during the year ended December 31, 2006 was \$7.39. There were 49,000 stock options granted in the corresponding period in 2005. The total intrinsic value of options exercised was \$1,272,000 and \$10,239,000 for the years ended December 31, 2006 and 2005, respectively.

As of December 31, 2006, total unrecognized stock-based compensation cost related to unvested stock options was \$4,739,000, which is expected to be expensed over a weighted-average period of 1.44 years.

Restricted Stock Purchase Rights: In 2003 and 2004, Apria granted restricted stock purchase rights to certain members of executive management. The awards represented the right to purchase a certain number of shares of Apria common stock at a future date at a specified exercise price. The exercise price was established at 25% of the fair market value of a share of Apria common stock on the date of grant. Such awards generally require that certain performance conditions and service conditions be met before the awards will vest.

The following table summarizes the activity for restricted stock purchase rights for the years ended December 31, 2004, 2005 and 2006:

	Restricted Stock Purchase Rights	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (in Years)	Aggregate Intrinsic Value
Outstanding at January 1, 2004.....	476,000	\$ 6.49		
Granted.....	110,000	7.60		
Exercised.....	—	—		
Forfeited.....	—	—		
Outstanding at December 31, 2004.....	586,000	\$ 6.70	8.71	\$15,385,350
Granted.....	—	—		
Exercised.....	(16,000)	6.46		
Forfeited.....	(24,000)	6.46		
Outstanding at December 31, 2005.....	546,000	\$ 6.71	7.72	\$ 9,499,110
Granted.....	—	—		
Exercised.....	(158,500)	6.49		
Forfeited.....	(87,500)	6.85		
Outstanding at December 31, 2006.....	300,000	\$ 6.79	6.76	\$ 5,957,820
Vested or expected to vest as of December 31, 2006.....	218,371	\$ 6.75	6.74	\$ 4,345,307
Exercisable at December 31, 2006.....	16,000	\$6.46	6.61	\$ 323,040

The total intrinsic value of restricted stock purchase rights exercised was \$2,592,000 and \$418,000 for the years ended December 31, 2006 and 2005, respectively. No such awards were granted during these two periods.

As of December 31, 2006, total unrecognized stock-based compensation cost related to unvested restricted stock purchase rights was \$3,503,000, which is expected to be expensed over a weighted-average period of 3.10 years.

Restricted Stock Awards and Units: Apria's incentive plan provides for the granting of restricted stock and restricted stock units to its non-employee directors and employees (limited to executive management). Such awards generally require that certain performance conditions and service conditions be met before the awards will vest.

The following table summarizes the activity for restricted stock awards and units for the years ended December 31, 2004, 2005 and 2006:

	Shares or Share Units	Weighted-Average Grant-Date Fair Value
Nonvested restricted stock awards and units at January 1, 2004	26,000	\$25.73
Granted	226,000	32.80
Vested and released	(26,000)	25.73
Forfeited	—	—
Nonvested restricted stock awards and units at December 31, 2004	226,000	32.80
Granted	81,384	34.98
Vested and released	(26,000)	28.21
Forfeited	—	—
Nonvested restricted stock awards and units at December 31, 2005	281,384	33.86
Granted	339,000	22.71
Vested and released	(38,462)	33.95
Forfeited	(95,000)	28.35
Nonvested restricted stock awards and units at December 31, 2006	486,922	\$27.16

The weighted-average fair value of restricted stock awards and units granted during the year ended December 31, 2006 was \$22.71. There were 81,384 awards granted in the corresponding period in 2005. Restricted stock awards or units released during the year ended December 31, 2006 and 2005, were 38,462 and 26,000 shares, respectively. The total intrinsic value of restricted stock awards or units released was \$768,000 and \$832,000 for the year ended December 31, 2006 and 2005, respectively.

As of December 31, 2006, total unrecognized stock-based compensation cost related to unvested restricted stock awards and units was \$9,388,000, which is expected to be expensed over a weighted-average period of 2.73 years.

Prior Period Pro Forma Presentation: Apria had previously adopted the provisions of SFAS No. 123 through disclosure only. The following table illustrates the effects on net income and earnings per share for the years ended December 31, 2005 and 2004 as if the company had applied the fair value recognition provisions of SFAS No. 123 to share-based employee awards.

(in thousands, except per share data)	Year Ended December 31,	
	2005	2004
Net income as reported	\$ 66,941	\$ 114,008
Add: stock-based compensation expense included in reported net income, net of related tax effects	2,032	2,828
Deduct: total stock-based compensation expense determined for all awards under fair value-based method, net of related tax effects	(13,070)	(12,869)
<i>Pro forma</i> net income	\$ 55,903	\$103,967
Basic net income per share:		
As reported	\$ 1.39	\$ 2.31
<i>Pro forma</i>	\$ 1.16	\$ 2.11
Diluted net income per share:		
As reported	\$ 1.37	\$ 2.27
<i>Pro forma</i>	\$ 1.14	\$ 2.07

The fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: risk-free interest rates of 3.78% and 3.19% for 2005 and 2004; respectively; dividend yield of 0% for both years; expected lives of 4.13 years for 2005 and 4.51 years in 2004; and volatility of 31.73% for 2005 and 42.58% for 2004.

Stock Option Acceleration: On November 30, 2005, the Compensation Committee of the Board of Directors of Apria approved the acceleration of vesting of certain outstanding employee stock options with per share prices above \$26.00, so that each such option became fully vested. As a result of this action, options to purchase 863,227 shares of Apria common stock became immediately exercisable. The accelerated options represented approximately 18.6% of Apria's total outstanding options at the time of the action.

The purpose of accelerating the vesting of these options was to eliminate the compensation expense that Apria would otherwise recognize in the consolidated statements of income in future financial statements with respect to these options upon the adoption of SFAS No. 123R. More than half of the accelerated options would have vested according to their terms during 2006 and more than 77% would have vested by February 2007. As a result of the acceleration, the company expects to reduce its future share-based compensation expense by approximately \$7,580,000.

Treasury Stock: All repurchased shares of common stock are held as treasury shares.

In 2006, 7,672 shares of employee restricted stock, valued at \$141,000, were retained by the company upon vesting to satisfy related tax obligations.

In October 2005, Apria's Board of Directors authorized the company to repurchase up to \$250,000,000 worth of its outstanding common stock. On November 7, 2005, Apria purchased 7,337,526 shares of its common stock for \$175,000,000 through an accelerated share repurchase program. Under the agreement, Apria's counterparty borrowed shares that were sold to Apria at an initial price of \$23.83. The counterparty then repurchased shares over a period that commenced immediately after the sale of shares to Apria. The repurchase transaction was completed in February 2006. The agreement contained a provision that subjected Apria to a purchase price adjustment based on the volume weighted average price of the company's common stock over the period during which the counterparty purchased the shares. Such provision resulted in an additional \$242,000 owed to the counterparty that Apria elected to settle in cash in February 2006. This amount was recorded as a liability at December 31, 2005, with a corresponding charge to interest expense reflecting the change in the fair value of the settlement contract. The amount remaining on the aforementioned Board authorization expires at the end of the first quarter of 2007.

In January 2004, Apria prepaid \$50,000,000 to repurchase 1,730,703 shares of its common stock at a strike price of \$28.89 through an accelerated share repurchase program. The repurchase of the shares was completed in April 2004 and the share price differential was settled in cash in June 2004, for a total cost of \$53,033,000. During the third quarter of 2004, the company purchased an additional 1,687,400 shares for \$46,967,000.

NOTE 8 — INCOME TAXES

Significant components of Apria's deferred tax assets and liabilities are as follows:

	December 31,	
(in thousands)	2006	2005
Deferred tax assets:		
Allowance for doubtful accounts.....	\$ 13,007	\$ 15,989
Accruals	14,021	12,955
Asset valuation reserves.....	14,301	8,622
Net operating loss carryforward.....	8,448	8,827
Intangible assets	8,994	8,423
Deferred revenue and expenses.....	3,735	—
Other, net.....	8,882	5,218
	71,388	60,034
Less: valuation allowance	(904)	(957)
Total deferred tax assets.....	70,484	59,077
Deferred tax liabilities:		
Tax over book depreciation	(28,213)	(29,491)
Tax over book goodwill amortization	(43,737)	(28,658)
Contingent debt interest	(19,353)	—
Other, net.....	(3,348)	(4,032)
Total deferred tax liabilities	(94,651)	(62,181)
Net deferred tax liabilities.....	\$(24,167)	\$ (3,104)

The ultimate realization of deferred tax assets is dependent upon the generation of future income during the periods in which temporary differences become deductible. In making an assessment regarding the probability of realizing a benefit from these deductible differences, management considers the company's current and past performance, the market environment in which the company operates, tax planning strategies and the length of carryforward periods.

During 2006, the valuation allowance decreased by \$53,000 due to the fact that state net operating loss carryforwards, that were previously expected to expire, became realizable.

Income tax expense (benefit) consists of the following:

	Year Ended December 31,		
(in thousands)	2006	2005	2004
Current:			
Federal	\$ 16,458	\$ 46,030	\$ 35,245
State	2,490	(719)	8,254
	18,948	45,311	43,499
Deferred:			
Federal	21,298	(5,605)	25,088
State	3,011	723	(4,290)
	24,309	(4,882)	20,798
	\$ 43,257	\$ 40,429	\$ 64,297

Differences between Apria's income tax expense and an amount calculated utilizing the federal statutory rate are as follows:

(in thousands)	Year Ended December 31,		
	2006	2005	2004
Income tax expense at statutory rate.....	\$ 41,382	\$ 37,580	\$ 62,407
Non-deductible expenses.....	711	2,958	465
State taxes, net of federal benefit and state loss carryforwards.....	5,134	4,592	7,071
Change in valuation allowance.....	(53)	(2,218)	(6,803)
Change in contingency reserve.....	(4,063)	(2,483)	959
Other	146	—	198
	\$ 43,257	\$ 40,429	\$ 64,297

Net income taxes paid in 2006, 2005 and 2004 amounted to \$16,406,000, \$52,099,000 and \$35,564,000, respectively.

The company believes it has adequately provided for income tax issues not yet resolved with federal, state and local tax authorities. At December 31, 2006, \$12,195,000, net of tax benefit, was accrued for such federal, state and local tax matters and is included in income taxes payable. Although not probable, the most adverse resolution of these federal, state and local issues could result in additional charges to earnings in future periods in addition to the \$12,195,000 currently provided. Based upon a consideration of all relevant facts and circumstances, the company does not believe the ultimate resolution of tax issues for all open tax periods will have a materially adverse effect upon its results of operations or financial condition.

NOTE 9 — PER SHARE AMOUNTS

The following table sets forth the computation of basic and diluted per share amounts:

(in thousands, except per share data)	Year Ended December 31,		
	2006	2005	2004
Numerator:			
Net income.....	\$ 74,980	\$ 66,941	\$ 114,008
Numerator for basic and diluted per share amounts — income available to common stockholders.....	\$ 74,980	\$ 66,941	\$ 114,008
Denominator:			
Denominator for basic per share amounts — weighted-average shares	42,462	48,154	49,368
Effect of dilutive securities:			
Employee stock options — dilutive potential common shares.....	473	831	812
Denominator for diluted per share amounts — adjusted weighted-average shares.....	42,935	48,985	50,180
Basic net income per common share.....	\$ 1.77	\$ 1.39	\$ 2.31
Diluted net income per common share.....	\$ 1.75	\$ 1.37	\$ 2.27
Employee stock options excluded from the computation of diluted per share amounts:			
Shares for which exercise price exceeds average market price of common stock	3,145	2,073	1,505
Average exercise price per share that exceeds average market price of common stock	\$26.71	\$30.21	\$31.66

NOTE 10 — LEASES

Apria leases all of its facilities. Lease terms are generally ten years or less with renewal options for additional periods. The company occasionally subleases unused facility space when a lease buyout is not a viable option. Sublease income is recognized monthly and is offset against facility lease expense. Sublease income in 2006, 2005 and 2004 amounted to \$1,046,000, \$988,000 and \$1,012,000, respectively. In addition, delivery vehicles and office equipment are leased under operating leases. Many leases provide that the company pay taxes, maintenance, insurance and other expenses. Rentals are generally increased annually by the Consumer Price Index, subject to certain maximum amounts defined within individual agreements. Net rent expense in 2006, 2005 and 2004 amounted to \$73,293,000, \$74,835,000 and \$72,330,000, respectively.

During 2004, Apria acquired information systems hardware and software totaling \$3,156,000 under capital lease arrangements with lease terms ranging from 24 to 36 months. Related amortization amounted to \$796,000, \$709,000 and \$229,000 in 2006, 2005 and 2004, respectively. There were no purchases of assets under capital lease arrangements during 2006 and 2005.

The following amounts for assets under capital lease obligations are included in property, equipment and improvements:

(in thousands)	December 31,	
	2006	2005
Information systems — hardware and software	\$ 3,156	\$ 3,156
Less accumulated depreciation	(1,734)	(938)
	\$ 1,422	\$ 2,218

Future minimum payments, by year and in the aggregate, required under noncancelable operating leases consist of the following at December 31, 2006:

(in thousands)	
2007.....	\$ 56,819
2008.....	46,841
2009.....	35,886
2010.....	26,145
2011.....	18,056
Thereafter	21,684
	\$205,431

NOTE 11 — EMPLOYEE BENEFIT PLANS

401(k) Savings Plan: Apria has a 401(k) defined contribution plan, whereby eligible employees may contribute up to 35% of their annual base earnings. During the two years ended 2005, the company matched 50% of the first 8% of employee contributions. Total expenses related to the defined contribution plan were \$4,970,000 and \$4,588,000 in 2005 and 2004, respectively. In 2006 the company suspended the employer match contribution.

Pension Plan: Apria contributes to a union pension fund in the state of New York, for which an unfunded liability of \$685,000 and \$706,000 was accrued at December 31, 2006 and 2005, respectively. This liability is classified in other non-current liabilities.

Deferred Compensation Plan: Apria has a non-qualified deferred compensation plan that is available for approximately 250 employees and members of the Board of Directors. The plan provides participants with the advantages of pre-tax contributions and tax deferred compounding of interest. Plan assets, which represent the fair market value of the investments, were \$4,966,000 and \$4,645,000, and plan liabilities were \$4,128,000 and \$3,947,000 at December 31, 2006 and 2005, respectively.

NOTE 12 — COMMITMENTS AND CONTINGENCIES

Litigation: Apria is the defendant in a California class action lawsuit containing blanket claims of liability under various California employee protection statutes and regulations relating to payment of regular and overtime wages, the timeliness of such payments, the maintenance and provision of access to required payroll records, and the provision of meal and rest periods. *Venegas vs. Apria Healthcare, Inc., et al.*, was filed on February 21, 2006 in the California Superior Court for the County of San Francisco (Case No. CGC — 06 — 449669). No class has been certified at this time, but on behalf of a purported class consisting of certain hourly employees of the company in the State of California, the complaint seeks compensatory and punitive damages in an unspecified amount as well as other relief. The company has filed an answer to the complaint denying all material allegations and asserting a number of affirmative defenses. Based on the company's preliminary investigation of the allegations, management believes there are meritorious defenses to the claims and the company intends to vigorously defend the lawsuit. No assurance can be given, however, that the ultimate disposition of this case will not have a material adverse effect on the company's financial condition or results of operations.

Apria is also engaged in the defense of certain claims and lawsuits arising out of the ordinary course and conduct of its business, the outcomes of which are not determinable at this time. Apria has insurance policies covering such potential losses where such coverage is cost effective. In the opinion of management, any liability that might be incurred by Apria upon the resolution of these claims and lawsuits will not, in the aggregate, have a material adverse effect on Apria's financial condition or results of operations.

Qui Tam Settlement and Related Costs: As previously reported, Apria was the subject of an investigation launched in mid-1998 by the U.S. Attorney's office in Los Angeles and the U.S. Department of Health and Human Services. The investigation concerned the documentation supporting Apria's billing for services provided to patients whose healthcare costs were paid by Medicare and other federal programs. The investigation related to two civil *qui tam* lawsuits against Apria filed by individuals suing on behalf of the government. Apria and representatives of the government and the individual plaintiffs reached a preliminary agreement in early August 2005 to settle these lawsuits for the aggregate sum of \$17,600,000, without any admission of wrongdoing by Apria. The settlement was finalized in a definitive agreement that was fully executed and became effective on September 30, 2005, and Apria paid the settlement amount on that date. Apria also incurred \$1,658,000 in legal fees and other related costs during 2005.

Medicare Reimbursement: There are a number of provisions contained within recent legislation or proposed legislation that affect or may affect Medicare reimbursement policies for items and services provided by Apria. The company cannot be certain of the ultimate impact of all legislated and contemplated changes, and therefore, cannot provide assurance that these changes will not have a material adverse effect on Apria's results of operations.

Supplier Concentration: Apria currently purchases approximately 59% of its patient service equipment and supplies from four vendors. Although there are a limited number of suppliers, management believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect operating results.

Guarantees and Indemnities: From time to time Apria enters into certain types of contracts that contingently require the company to indemnify parties against third party claims. These contracts primarily relate to (i) certain asset purchase agreements, under which the company may provide customary indemnification to the seller of the business being acquired; (ii) certain real estate leases, under which the company may be required to indemnify property owners for environmental or other liabilities, and other claims arising from the company's use of the applicable premises; and (iii) certain agreements with the company's officers, directors and employees, under which the company may be required to indemnify such persons for liabilities arising out of their relationship with the company.

The terms of such obligations vary by contract and in most instances a specific or maximum dollar amount is not explicitly stated therein. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, no liabilities have been recorded for these obligations on the company's balance sheets for any of the periods presented.

NOTE 13 — SERVICE/PRODUCT LINE DATA

The following table sets forth a summary of net revenues and gross profit by service line:

	Year Ended December 31,		
(in thousands)	2006	2005	2004
Net revenues:			
Respiratory therapy.....	\$ 1,033,267	\$ 1,009,752	\$ 990,857
Infusion therapy	274,723	256,225	246,662
Home medical equipment/other.....	209,317	208,124	213,930
Total net revenues.....	\$1,517,307	\$1,474,101	\$ 1,451,449
Gross profit:			
Respiratory therapy.....	\$ 737,476	\$ 746,486	\$ 774,149
Infusion therapy	146,121	131,128	129,482
Home medical equipment/other.....	112,271	117,199	130,374
Total gross profit	\$ 995,868	\$ 994,813	\$ 1,034,005

Net revenues for 2006 reflect Medicare reimbursement reductions of \$15.0 million on respiratory drugs and dispensing fees plus oxygen and oxygen related equipment. Net revenues for 2005 reflect Medicare reimbursement reductions of \$27.4 million on respiratory medications, certain durable medical equipment items and oxygen and oxygen-related equipment. Respiratory therapy revenues for 2004 reflect Medicare reimbursement reductions of \$15.2 million on respiratory medications.

Respiratory therapy and total gross profit for 2004 are not comparable to the other years presented. For 2006 and 2005, certain respiratory therapy costs were reclassified from selling, distribution and administrative expense to cost of net revenues, however, the corresponding reclassification was not made for 2004. See “Note 1 — Respiratory Therapy Expenses.”

NOTE 14 — SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

	Quarter			
(in thousands, except per share data)	First	Second	Third	Fourth
2006				
Net revenues.....	\$ 368,056	\$ 376,079	\$ 382,214	\$ 390,958
Gross profit	241,082	247,109	251,120	256,557
Operating income.....	31,944	37,355	38,209	40,192
Net income.....	16,123	18,458	19,306	21,093
Basic net income per common share.....	\$ 0.38	\$ 0.44	\$ 0.45	\$ 0.50
Diluted net income per common share.....	\$ 0.38	\$ 0.43	\$ 0.45	\$ 0.49
2005				
Net revenues.....	\$ 371,863	\$ 374,931	\$ 367,615	\$ 359,692
Gross profit	252,092	255,348	248,922	238,451
Operating income.....	40,768	21,589	33,360	33,772
Net income.....	25,170	3,016	19,255	19,500
Basic net income per common share.....	\$ 0.52	\$ 0.06	\$ 0.39	\$ 0.42
Diluted net income per common share.....	\$ 0.51	\$ 0.06	\$ 0.38	\$ 0.42

Net income for the second quarter of 2005 was impacted by the initial accrual of \$20,000,000 for the settlement costs and legal fees associated with the federal investigation and qui tam lawsuits. The initial accrual recorded was subsequently adjusted to \$19,258,000 in the fourth quarter. See “Note 12 — Commitments and Contingencies.”

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Apria Healthcare Group Inc.
Lake Forest, California

We have audited management's assessment, included in the accompanying Management's Report on Internal Control Over Financial Reporting that Apria Healthcare Group, Inc. and subsidiaries (the "Company") maintained effective internal control over financial reporting as of December 31, 2006, based on criteria established in *Internal Control — Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission. The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting. Our responsibility is to express an opinion on management's assessment and an opinion on the effectiveness of the Company's internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, evaluating management's assessment, testing and evaluating the design and operating effectiveness of internal control, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinions.

A company's internal control over financial reporting is a process designed by, or under the supervision of, the company's principal executive and principal financial officers, or persons performing similar functions, and effected by the company's board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, management's assessment that the Company maintained effective internal control over financial reporting as of December 31, 2006, is fairly stated, in all material respects, based on the criteria established in *Internal Control — Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2006, based on the criteria established in *Internal Control — Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated financial statements as of and for the year ended December 31, 2006 of the Company and our report dated March 1, 2007 expressed an unqualified opinion on those financial statements and included an explanatory paragraph regarding the Company's adoption of a new accounting standard, Statement of Financial Accounting Standards No. 123(R), Share-Based Payment, and the Company's adoption of Staff Accounting Bulletin No. 108, *Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements*.

Deloitte + Touche LLP

Costa Mesa, California
March 1, 2007

Management's Report on Internal Control Over Financial Reporting

Apria's management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). The company's internal control over financial reporting system is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance that material misstatements will be prevented or detected on a timely basis. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of management, including the principal executive and financial officers, the company has conducted an evaluation of the effectiveness of its internal control over financial reporting based on the framework in *Internal Control — Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management has concluded that its internal control over financial reporting was effective as of December 31, 2006.


Management's assessment of the effectiveness of internal control over financial reporting as of December 31, 2006 has been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in its report on management's assessment of Apria's internal control over financial reporting, which is included herein.

March 1, 2007

TOTAL RETURN COMPARISON

The following graph shows the changes over the last five-year period in the value of \$100 invested in (i) the common stock of Apria, (ii) the S&P 500 Stock Index, and (iii) the Peer Group Index¹. The value of each investment is based on share price appreciation, with reinvestment of all dividends. The investments are assumed to have occurred at the beginning of the period presented.

COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*



¹ The Peer Group Index is based on the cumulative total returns of the following companies: American HomePatient, Inc., Coram Healthcare Corporation, Lincare Holdings, Inc., Option Care, Inc., and Rotech Healthcare, Inc. Coram Healthcare Corporation's stock ceased being publicly traded in 2005 and its returns are therefore included only through December 31, 2004. Rotech Healthcare, Inc.'s returns are included only as of December 31, 2004, to reflect the time at which Rotech became listed on the Nasdaq.

*\$100 invested on 12/31/01 in stock or index-including reinvestment of dividends. Fiscal year ending December 31.

©2007 Standard & Poor's, a division of The McGraw-Hill Companies, Inc. All rights reserved.

	December,					
	2001	2002	2003	2004	2005	2006
Apria Healthcare Group Inc.....	100.00	89.00	113.93	131.85	96.48	106.64
S & P 500.....	100.00	77.90	100.24	111.15	116.61	135.03
Peer Group	100.00	105.68	103.20	148.12	139.02	123.14

It should be noted that this graph represents historical stock price performance and is not necessarily indicative of any future stock price performance.

The performance graph that appears above shall not be deemed to be soliciting material or to be filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended, or the Exchange Act, or incorporated by reference in any document so filed.

Corporate and Investor Information

Lawrence M. Higby
Chief Executive Officer



Lawrence A. Mastrovich
President and
Chief Operating Officer



Chris A. Karkenny
Executive Vice President and
Chief Financial Officer



Robin L. Barton
Executive Vice President,
Revenue Management



Lisa M. Getson
Executive Vice President,
Government Relations, Investor
Services and Compliance



Robert S. Holcombe
Executive Vice President,
General Counsel and
Secretary



W. Jeffrey Ingram
Executive Vice President,
Sales



Jeri L. Lose
Executive Vice President,
Chief Information Officer



A. Cameron Thompson
Executive Vice President,
Logistics

SENIOR VICE PRESIDENTS

Frank C. Bianchi
Senior Vice President,
Human Resources

Anthony F. Giambone
Senior Vice President,
Enterprise Business Systems

Vanessa L. Pfeiffer
Senior Vice President,
Marketing and Sales
Planning

Kimberlie K. Rogers-Bowers
Senior Vice President,
Regulatory Affairs and
Acquisition Integration

STOCK TRADING INFORMATION

The company's common stock is traded on the New York Stock Exchange under the symbol AHG.

REQUIRED CERTIFICATIONS

Apria has filed with the Securities and Exchange Commission its Sarbanes-Oxley Act Section 302 Certifications regarding the quality of the company's public disclosure as exhibits to its Annual Report on Form 10-K for the year ended December 31, 2006. Apria also submitted to the New York Stock Exchange the annual certification of its Chief Executive Officer for 2006 to the effect that he was not aware of any violation by the company of the New York Stock Exchange's corporate governance listing standards.

STOCK TRANSFER AGENT AND REGISTRAR

American Stock Transfer & Trust Co., 59 Maiden Lane, New York 10038, Phone: (800) 937-5449 or (718) 921-8200
Web address: www.amstock.com

CORPORATE HEADQUARTERS

26220 Enterprise Court, Lake Forest, California 92630-8405, Phone: (949) 639-2000

FORM 10-K

A copy of the company's Annual Report on Form 10-K (without exhibits) for the fiscal year ended December 31, 2006, which the company has filed with the Securities and Exchange Commission, may be obtained by calling Apria's Investor Relations Department at (949) 639-2415 or mailing a written request to: Apria Healthcare Group Inc. Investor Requests, 26220 Enterprise Court, Lake Forest, California 92630-8405. A copy of the Annual Report on Form 10-K may also be obtained in the "About Apria"/"Investor Relations" section of Apria's website: www.apria.com.

BOARD OF DIRECTORS

David L. Goldsmith⁽¹⁾

Private Investor

Vicente Anido, Jr.⁽²⁾

President and Chief Executive Officer
ISTA Pharmaceuticals, Inc., an ophthalmic
pharmaceutical manufacturer

Terry P. Bayer⁽³⁾

Chief Operating Officer
Molina Healthcare, Inc., a multi-state
managed care organization

I.T. Corley⁽⁴⁾

President and Chief Executive Officer
SMI Group Holdings, Inc.
a glass recycler and processor

Lawrence M. Higby

Chief Executive Officer
Apria Healthcare

Richard H. Koppes⁽⁵⁾

Of Counsel
Jones Day, a law firm

Philip R. Lochner, Jr.⁽⁶⁾

Senior Vice President, Administration
Time Warner Inc., a multimedia
company (retired)

Norman C. Payson, M.D.⁽⁷⁾

Chairman
Concentra Operating Corporation,
an occupational healthcare
services company

Mahvash Yazdi⁽⁸⁾

Senior Vice President of
Business Integration and
Chief Information Officer
Edison International,
a global energy services company

(1) Chairman of the Board; Member,
Audit Committee

(2) Member, Corporate Governance and
Nominating Committee; Member,
Compensation Committee

(3) Chairman, Compliance
Committee; Member,
Compensation Committee

(4) Chairman, Audit Committee;
Member, Compliance
Committee

(5) Chairman, Corporate
Governance and Nominating
Committee; Member,
Compensation Committee

(6) Chairman, Compensation
Committee; Member, Audit
Committee

(7) Member, Compensation Committee;
Member, Compliance Committee

(8) Member, Audit Committee;
Member, Corporate Governance and
Nominating Committee

